

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 20:38:24 ON 31 AUG 2006
FILE 'CAPLUS' ENTERED AT 20:38:24 ON 31 AUG 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	401.06	976.67

	SINCE FILE	TOTAL
	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	-25.50	-30.75

=> s us2005261298/pn
L32 2 US2005261298/PN

=> s 143:472565/dn
L33 1 143:472565/DN

=> d rn

L33 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
RN 60-92-4
RN 127464-60-2
RN 40622-01-3P
RN 66085-59-4P
RN 306764-68-1P
RN 312501-62-5P
RN 331945-22-3P
RN 353771-45-6P
RN 91-56-5
RN 108-31-6
RN 108-38-3
RN 119-80-2
RN 619-05-6
RN 1226-42-2
RN 4506-71-2
RN 5242-26-2
RN 64900-65-8
RN 82799-44-8
RN 569656-05-9
RN 569656-06-0
RN 7741-54-0P
RN 76293-13-5P
RN 569656-29-7P
RN 7440-70-2

=> select l33
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E210 THROUGH E233 ASSIGNED

=> d sel

E1	1	108-31-6/BI
E2	1	108-38-3/BI
E3	1	119-80-2/BI
E4	1	1226-42-2/BI
E5	1	127464-60-2/BI
E6	1	306764-68-1/BI
E7	1	312501-62-5/BI
E8	1	331945-22-3/BI
E9	1	353771-45-6/BI
E10	1	40622-01-3/BI
E11	1	4506-71-2/BI
E12	1	5242-26-2/BI
E13	1	569656-05-9/BI
E14	1	569656-06-0/BI
E15	1	569656-29-7/BI
E16	1	60-92-4/BI
E17	1	619-05-6/BI
E18	1	64900-65-8/BI
E19	1	66085-59-4/BI
E20	1	7440-70-2/BI
E21	1	76293-13-5/BI
E22	1	7741-54-0/BI
E23	1	82799-44-8/BI
E24	1	91-56-5/BI
E25	1	108-31-6/BI
E26	1	108-38-3/BI
E27	1	119-80-2/BI
E28	1	1226-42-2/BI
E29	1	127464-60-2/BI
E30	1	306764-68-1/BI
E31	1	312501-62-5/BI
E32	1	331945-22-3/BI
E33	1	353771-45-6/BI
E34	1	40622-01-3/BI
E35	1	4506-71-2/BI
E36	1	5242-26-2/BI
E37	1	569656-05-9/BI
E38	1	569656-06-0/BI
E39	1	569656-29-7/BI
E40	1	60-92-4/BI
E41	1	619-05-6/BI
E42	1	64900-65-8/BI
E43	1	66085-59-4/BI
E44	1	7440-70-2/BI
E45	1	76293-13-5/BI
E46	1	7741-54-0/BI
E47	1	82799-44-8/BI
E48	1	91-56-5/BI
E49	1	100-65-2/BI
E50	1	107235-67-6/BI
E51	1	108-31-6/BI
E52	1	108-38-3/BI
E53	1	112612-58-5/BI
E54	1	113054-02-7/BI
E55	1	120-72-9/BI
E56	1	1226-42-2/BI
E57	1	123-11-5/BI
E58	1	127464-60-2/BI
E59	1	13100-05-5/BI
E60	1	13380-67-1/BI
E61	1	136382-28-0/BI
E62	1	140-75-0/BI

E63	1	1468-83-3/BI
E64	1	1476-23-9/BI
E65	1	149246-80-0/BI
E66	1	149246-86-6/BI
E67	1	1572-10-7/BI
E68	1	171286-07-0/BI
E69	1	173275-26-8/BI
E70	1	177360-28-0/BI
E71	1	182762-25-0/BI
E72	1	19541-95-8/BI
E73	1	208519-10-2/BI
E74	1	208519-15-7/BI
E75	1	218763-60-1/BI
E76	1	23448-86-4/BI
E77	1	23821-37-6/BI
E78	1	259476-69-2/BI
E79	1	262400-57-7/BI
E80	1	2642-63-9/BI
E81	1	26993-30-6/BI
E82	1	292076-38-1/BI
E83	1	302-01-2/BI
E84	1	304650-31-5/BI
E85	1	306764-68-1/BI
E86	1	309282-30-2/BI
E87	1	311773-65-6/BI
E88	1	311799-07-2/BI
E89	1	312501-62-5/BI
E90	1	312519-16-7/BI
E91	1	312594-43-7/BI
E92	1	321679-76-9/BI
E93	1	322662-05-5/BI
E94	1	327167-87-3/BI
E95	1	329069-72-9/BI
E96	1	329350-38-1/BI
E97	1	330630-42-7/BI
E98	1	331274-84-1/BI
E99	1	331945-22-3/BI
E100	1	332161-39-4/BI
E101	1	334498-72-5/BI
E102	1	337349-59-4/BI
E103	1	337469-26-8/BI
E104	1	337498-14-3/BI
E105	1	342384-25-2/BI
E106	1	346699-98-7/BI
E107	1	353253-35-7/BI
E108	1	353273-74-2/BI
E109	1	353463-50-0/BI
E110	1	353771-45-6/BI
E111	1	353793-15-4/BI
E112	1	355000-90-7/BI
E113	1	363-58-6/BI
E114	1	364051-15-0/BI
E115	1	36817-57-9/BI
E116	1	372-31-6/BI
E117	1	383164-60-1/BI
E118	1	384729-36-6/BI
E119	1	385223-15-4/BI
E120	1	389079-78-1/BI
E121	1	390105-18-7/BI
E122	1	390174-36-4/BI
E123	1	390523-03-2/BI
E124	1	39151-19-4/BI
E125	1	392101-34-7/BI

E126	1	400064-03-1/BI
E127	1	406-00-8/BI
E128	1	40622-01-3/BI
E129	1	43071-45-0/BI
E130	1	434-75-3/BI
E131	1	4506-71-2/BI
E132	1	473390-98-6/BI
E133	1	49843-94-9/BI
E134	1	50-30-6/BI
E135	1	50-45-3/BI
E136	1	502132-61-8/BI
E137	1	5242-26-2/BI
E138	1	533-18-6/BI
E139	1	5351-85-9/BI
E140	1	5351-91-7/BI
E141	1	5467-70-9/BI
E142	1	556-90-1/BI
E143	1	569655-94-3/BI
E144	1	569655-95-4/BI
E145	1	569655-96-5/BI
E146	1	569655-97-6/BI
E147	1	569655-98-7/BI
E148	1	569655-99-8/BI
E149	1	569656-00-4/BI
E150	1	569656-01-5/BI
E151	1	569656-02-6/BI
E152	1	569656-03-7/BI
E153	1	569656-04-8/BI
E154	1	569656-05-9/BI
E155	1	569656-06-0/BI
E156	1	569656-07-1/BI
E157	1	569656-08-2/BI
E158	1	569656-09-3/BI
E159	1	569656-10-6/BI
E160	1	569656-11-7/BI
E161	1	569656-12-8/BI
E162	1	569656-13-9/BI
E163	1	569656-14-0/BI
E164	1	569656-15-1/BI
E165	1	569656-16-2/BI
E166	1	569656-17-3/BI
E167	1	569656-18-4/BI
E168	1	569656-19-5/BI
E169	1	569656-20-8/BI
E170	1	569656-21-9/BI
E171	1	569656-22-0/BI
E172	1	569656-23-1/BI
E173	1	569656-24-2/BI
E174	1	569656-25-3/BI
E175	1	569656-26-4/BI
E176	1	569656-27-5/BI
E177	1	569656-28-6/BI
E178	1	569656-29-7/BI
E179	1	60-92-4/BI
E180	1	619-05-6/BI
E181	1	619-41-0/BI
E182	1	6292-74-6/BI
E183	1	64900-65-8/BI
E184	1	6629-60-3/BI
E185	1	70-11-1/BI
E186	1	72411-52-0/BI
E187	1	7420-34-0/BI
E188	1	7440-70-2/BI

E189	1	76293-13-5/BI
E190	1	7741-53-9/BI
E191	1	7741-54-0/BI
E192	1	79-19-6/BI
E193	1	82799-44-8/BI
E194	1	82799-45-9/BI
E195	1	829-20-9/BI
E196	1	83-38-5/BI
E197	1	86358-85-2/BI
E198	1	89570-85-4/BI
E199	1	90212-73-0/BI
E200	1	91-56-5/BI
E201	1	91912-53-7/BI
E202	1	93-17-4/BI
E203	1	93-55-0/BI
E204	1	94835-69-5/BI
E205	1	96799-03-0/BI
E206	1	96799-04-1/BI
E207	1	98-59-9/BI
E208	1	98-88-4/BI
E209	1	98-95-3/BI
E210	1	108-31-6/BI
E211	1	108-38-3/BI
E212	1	119-80-2/BI
E213	1	1226-42-2/BI
E214	1	127464-60-2/BI
E215	1	306764-68-1/BI
E216	1	312501-62-5/BI
E217	1	331945-22-3/BI
E218	1	353771-45-6/BI
E219	1	40622-01-3/BI
E220	1	4506-71-2/BI
E221	1	5242-26-2/BI
E222	1	569656-05-9/BI
E223	1	569656-06-0/BI
E224	1	569656-29-7/BI
E225	1	60-92-4/BI
E226	1	619-05-6/BI
E227	1	64900-65-8/BI
E228	1	66085-59-4/BI
E229	1	7440-70-2/BI
E230	1	76293-13-5/BI
E231	1	7741-54-0/BI
E232	1	82799-44-8/BI
E233	1	91-56-5/BI

=> e1-e233

E1-E233 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s e1-e233

34885	108-31-6/BI
17010	108-38-3/BI
365	119-80-2/BI
596	1226-42-2/BI
15362	127464-60-2/BI
3	306764-68-1/BI
3	312501-62-5/BI
3	331945-22-3/BI
3	353771-45-6/BI

9 40622-01-3/BI
258 4506-71-2/BI
8 5242-26-2/BI
3 569656-05-9/BI
3 569656-06-0/BI
3 569656-29-7/BI
59933 60-92-4/BI
453 619-05-6/BI
104 64900-65-8/BI
2259 66085-59-4/BI
375926 7440-70-2/BI
73 76293-13-5/BI
4 7741-54-0/BI
620 82799-44-8/BI
2647 91-56-5/BI
34885 108-31-6/BI
17010 108-38-3/BI
365 119-80-2/BI
596 1226-42-2/BI
15362 127464-60-2/BI
3 306764-68-1/BI
3 312501-62-5/BI
3 331945-22-3/BI
3 353771-45-6/BI
9 40622-01-3/BI
258 4506-71-2/BI
8 5242-26-2/BI
3 569656-05-9/BI
3 569656-06-0/BI
3 569656-29-7/BI
59933 60-92-4/BI
453 619-05-6/BI
104 64900-65-8/BI
2259 66085-59-4/BI
375926 7440-70-2/BI
73 76293-13-5/BI
4 7741-54-0/BI
620 82799-44-8/BI
2647 91-56-5/BI
1137 100-65-2/BI
3 107235-67-6/BI
34885 108-31-6/BI
17010 108-38-3/BI
3 112612-58-5/BI
4 113054-02-7/BI
12946 120-72-9/BI
596 1226-42-2/BI
17537 123-11-5/BI
15362 127464-60-2/BI
25 13100-05-5/BI
148 13380-67-1/BI
5 136382-28-0/BI
778 140-75-0/BI
268 1468-83-3/BI
650 1476-23-9/BI
4 149246-80-0/BI
5 149246-86-6/BI
328 1572-10-7/BI
4 171286-07-0/BI
4 173275-26-8/BI
5 177360-28-0/BI
6 182762-25-0/BI
49 19541-95-8/BI

5 208519-10-2/BI
4 208519-15-7/BI
15 218763-60-1/BI
10 23448-86-4/BI
12 23821-37-6/BI
10 259476-69-2/BI
1 262400-57-7/BI
275 2642-63-9/BI
1187 26993-30-6/BI
2 292076-38-1/BI
23190 302-01-2/BI
2 304650-31-5/BI
3 306764-68-1/BI
4 309282-30-2/BI
2 311773-65-6/BI
2 311799-07-2/BI
3 312501-62-5/BI
2 312519-16-7/BI
2 312594-43-7/BI
1 321679-76-9/BI
3 322662-05-5/BI
1 327167-87-3/BI
3 329069-72-9/BI
2 329350-38-1/BI
3 330630-42-7/BI
1 331274-84-1/BI
3 331945-22-3/BI
2 332161-39-4/BI
2 334498-72-5/BI
2 337349-59-4/BI
2 337469-26-8/BI
2 337498-14-3/BI
1 342384-25-2/BI
2 346699-98-7/BI
3 353253-35-7/BI
3 353273-74-2/BI
2 353463-50-0/BI
3 353771-45-6/BI
3 353793-15-4/BI
2 355000-90-7/BI
55 363-58-6/BI
2 364051-15-0/BI
7 36817-57-9/BI
662 372-31-6/BI
3 383164-60-1/BI
5 384729-36-6/BI
18 385223-15-4/BI
2 389079-78-1/BI
5 390105-18-7/BI
4 390174-36-4/BI
5 390523-03-2/BI
132 39151-19-4/BI
4 392101-34-7/BI
2 400064-03-1/BI
28 406-00-8/BI
9 40622-01-3/BI
32 43071-45-0/BI
60 434-75-3/BI
258 4506-71-2/BI
3 473390-98-6/BI
8 49843-94-9/BI
350 50-30-6/BI
146 50-45-3/BI

2 502132-61-8/BI
8 5242-26-2/BI
190 533-18-6/BI
37 5351-85-9/BI
91 5351-91-7/BI
39 5467-70-9/BI
266 556-90-1/BI
2 569655-94-3/BI
2 569655-95-4/BI
2 569655-96-5/BI
1 569655-97-6/BI
2 569655-98-7/BI
3 569655-99-8/BI
3 569656-00-4/BI
2 569656-01-5/BI
2 569656-02-6/BI
2 569656-03-7/BI
1 569656-04-8/BI
3 569656-05-9/BI
3 569656-06-0/BI
1 569656-07-1/BI
2 569656-08-2/BI
1 569656-09-3/BI
2 569656-10-6/BI
2 569656-11-7/BI
2 569656-12-8/BI
2 569656-13-9/BI
2 569656-14-0/BI
2 569656-15-1/BI
1 569656-16-2/BI
2 569656-17-3/BI
2 569656-18-4/BI
2 569656-19-5/BI
2 569656-20-8/BI
2 569656-21-9/BI
1 569656-22-0/BI
3 569656-23-1/BI
3 569656-24-2/BI
2 569656-25-3/BI
3 569656-26-4/BI
3 569656-27-5/BI
2 569656-28-6/BI
3 569656-29-7/BI
59933 60-92-4/BI
453 619-05-6/BI
892 619-41-0/BI
11 6292-74-6/BI
104 64900-65-8/BI
74 6629-60-3/BI
5590 70-11-1/BI
7 72411-52-0/BI
6 7420-34-0/BI
375926 7440-70-2/BI
73 76293-13-5/BI
6 7741-53-9/BI
4 7741-54-0/BI
3537 79-19-6/BI
620 82799-44-8/BI
3 82799-45-9/BI
258 829-20-9/BI
1112 83-38-5/BI
6 86358-85-2/BI
19 89570-85-4/BI

3 90212-73-0/BI
 2647 91-56-5/BI
 8 91912-53-7/BI
 406 93-17-4/BI
 4059 93-55-0/BI
 5 94835-69-5/BI
 20 96799-03-0/BI
 6 96799-04-1/BI
 7795 98-59-9/BI
 15966 98-88-4/BI
 20313 98-95-3/BI
 34885 108-31-6/BI
 17010 108-38-3/BI
 365 119-80-2/BI
 596 1226-42-2/BI
 15362 127464-60-2/BI
 3 306764-68-1/BI
 3 312501-62-5/BI
 3 331945-22-3/BI
 3 353771-45-6/BI
 9 40622-01-3/BI
 258 4506-71-2/BI
 8 5242-26-2/BI
 3 569656-05-9/BI
 3 569656-06-0/BI
 3 569656-29-7/BI
 59933 60-92-4/BI
 453 619-05-6/BI
 104 64900-65-8/BI
 2259 66085-59-4/BI
 375926 7440-70-2/BI
 73 76293-13-5/BI
 4 7741-54-0/BI
 620 82799-44-8/BI
 2647 91-56-5/BI
 L34 610421 (108-31-6/BI OR 108-38-3/BI OR 119-80-2/BI OR 1226-42-2/BI OR
 127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22-
 3/BI OR 353771-45-6/BI OR 40622-01-3/BI OR 4506-71-2/BI OR 5242-2
 6-2/BI OR 569656-05-9/BI OR 569656-06-0/BI OR 569656-29-7/BI OR
 60-92-4/BI OR 619-05-6/BI OR 64900-65-8/BI OR 66085-59-4/BI OR
 7440-70-2/BI OR 76293-13-5/BI OR 7741-54-0/BI OR 82799-44-8/BI
 OR 91-56-5/BI OR 108-31-6/BI OR 108-38-3/BI OR 119-80-2/BI OR
 1226-42-2/BI OR 127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/B
 I OR 331945-22-3/BI OR 353771-45-6/BI OR 40622-01-3/BI OR 4506-71
 -2/BI OR 5242-26-2/BI OR 569656-05-9/BI OR 569656-06-0/BI OR
 569656-29-7/BI OR 60-92-4/BI OR 619-05-6/BI OR 64900-65-8/BI OR
 66085-59-4/BI OR 7440-70-2/BI OR 76293-13-5/BI OR 7741-54-0/BI
 OR 82799-44-8/BI OR 91-56-5/BI OR 100-65-2/BI OR 107235-67-6/BI
 OR 108-31-6/BI OR 108-38-3/BI OR 112612-58-5/BI OR 113054-02-7/BI
 OR 120-72-9/BI OR 1226-42-2/BI OR 123-11-5/BI OR 127464-60-2/BI
 OR 13100-05-5/BI OR 13380-67-1/BI

=> s 134 and (cancer or tumor or cancer? or tumour or neoplastic or neoplasm?)

289571 CANCER
 42241 CANCERS
 300561 CANCER
 (CANCER OR CANCERS)
 381334 TUMOR
 149800 TUMORS
 428933 TUMOR
 (TUMOR OR TUMORS)
 304222 CANCER?
 2925 TUMOUR

```

1107 TUMOURS
3972 TUMOUR
      (TUMOUR OR TUMOURS)
55897 NEOPLASTIC
      14 NEOPLASTICS
55907 NEOPLASTIC
      (NEOPLASTIC OR NEOPLASTICS)
433581 NEOPLASM?
L35    24165 L34 AND (CANCER OR TUMOR OR CANCER? OR TUMOUR OR NEOPLASTIC OR
      NEOPLASM? )

```

```

=> s l35 and edg
      901 EDG
      25 EDGS
      916 EDG
      (EDG OR EDGS)
L36    107 L35 AND EDG

```

```

=> focus
PROCESSING COMPLETED FOR L36
L37    107 FOCUS L36 1-

```

```

=> s e5-e9, e13-e15, e18-e22, e29-e33, e37-e39, e42-e43, e45-e47, e45-e47, e50,
e53-54, e58-e60, e68-e72, e84-e112, e117-e131
15362 127464-60-2/BI
      3 306764-68-1/BI
      3 312501-62-5/BI
      3 331945-22-3/BI
      3 353771-45-6/BI
      3 569656-05-9/BI
      3 569656-06-0/BI
      3 569656-29-7/BI
      104 64900-65-8/BI
      2259 66085-59-4/BI
375926 7440-70-2/BI
      73 76293-13-5/BI
      4 7741-54-0/BI
15362 127464-60-2/BI
      3 306764-68-1/BI
      3 312501-62-5/BI
      3 331945-22-3/BI
      3 353771-45-6/BI
      3 569656-05-9/BI
      3 569656-06-0/BI
      3 569656-29-7/BI
      104 64900-65-8/BI
      2259 66085-59-4/BI
      73 76293-13-5/BI
      4 7741-54-0/BI
      620 82799-44-8/BI
      73 76293-13-5/BI
      4 7741-54-0/BI
      620 82799-44-8/BI
      3 107235-67-6/BI
      3 112612-58-5/BI
      4 113054-02-7/BI
15362 127464-60-2/BI
      25 13100-05-5/BI
      148 13380-67-1/BI
      4 171286-07-0/BI
      4 173275-26-8/BI
      5 177360-28-0/BI
      6 182762-25-0/BI

```

49 19541-95-8/BI
 2 304650-31-5/BI
 3 306764-68-1/BI
 4 309282-30-2/BI
 2 311773-65-6/BI
 2 311799-07-2/BI
 3 312501-62-5/BI
 2 312519-16-7/BI
 2 312594-43-7/BI
 1 321679-76-9/BI
 3 322662-05-5/BI
 1 327167-87-3/BI
 3 329069-72-9/BI
 2 329350-38-1/BI
 3 330630-42-7/BI
 1 331274-84-1/BI
 3 331945-22-3/BI
 2 332161-39-4/BI
 2 334498-72-5/BI
 2 337349-59-4/BI
 2 337469-26-8/BI
 2 337498-14-3/BI
 1 342384-25-2/BI
 2 346699-98-7/BI
 3 353253-35-7/BI
 3 353273-74-2/BI
 2 353463-50-0/BI
 3 353771-45-6/BI
 3 353793-15-4/BI
 2 355000-90-7/BI
 3 383164-60-1/BI
 5 384729-36-6/BI
 18 385223-15-4/BI
 2 389079-78-1/BI
 5 390105-18-7/BI
 4 390174-36-4/BI
 5 390523-03-2/BI
 132 39151-19-4/BI
 4 392101-34-7/BI
 2 400064-03-1/BI
 28 406-00-8/BI
 9 40622-01-3/BI
 32 43071-45-0/BI
 60 434-75-3/BI
 258 4506-71-2/BI

L38 394370 (127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22-3/BI OR 353771-45-6/BI OR 569656-05-9/BI OR 569656-06-0/BI OR 569656-29-7/BI OR 64900-65-8/BI OR 66085-59-4/BI OR 7440-70-2/BI OR 76293-13-5/BI OR 7741-54-0/BI OR 127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22-3/BI OR 353771-45-6/BI OR 569656-05-9/BI OR 569656-06-0/BI OR 569656-29-7/BI OR 64900-65-8/BI OR 66085-59-4/BI OR 76293-13-5/BI OR 7741-54-0/BI OR 82799-44-8/BI OR 82799-44-8/BI OR 107235-67-6/BI OR 112612-58-5/BI OR 113054-02-7/BI OR 127464-60-2/BI OR 13100-05-5/BI OR 13380-67-1/BI OR 171286-07-0/BI OR 173275-26-8/BI OR 177360-28-0/BI OR 182762-25-0/BI OR 19541-95-8/BI OR 304650-31-5/BI OR 306764-68-1/BI OR 309282-30-2/BI OR 311773-65-6/BI OR 311799-07-2/BI OR 312501-62-5/BI OR 312519-16-7/BI OR 312594-43-7/BI OR 321679-76-9/BI OR 322662-05-5/BI OR 327167-87-3/BI OR 329069-72-9/BI OR 329350-38-1/BI OR 330630-42-7/BI OR 331274-84-1/BI OR 331945

=> s e143-e178, e197-e199, e204-206, e214-218, e227-229

2 569655-94-3/BI
 2 569655-95-4/BI
 2 569655-96-5/BI
 1 569655-97-6/BI
 2 569655-98-7/BI
 3 569655-99-8/BI
 3 569656-00-4/BI
 2 569656-01-5/BI
 2 569656-02-6/BI
 2 569656-03-7/BI
 1 569656-04-8/BI
 3 569656-05-9/BI
 3 569656-06-0/BI
 1 569656-07-1/BI
 2 569656-08-2/BI
 1 569656-09-3/BI
 2 569656-10-6/BI
 2 569656-11-7/BI
 2 569656-12-8/BI
 2 569656-13-9/BI
 2 569656-14-0/BI
 2 569656-15-1/BI
 1 569656-16-2/BI
 2 569656-17-3/BI
 2 569656-18-4/BI
 2 569656-19-5/BI
 2 569656-20-8/BI
 2 569656-21-9/BI
 1 569656-22-0/BI
 3 569656-23-1/BI
 3 569656-24-2/BI
 2 569656-25-3/BI
 3 569656-26-4/BI
 3 569656-27-5/BI
 2 569656-28-6/BI
 3 569656-29-7/BI
 6 86358-85-2/BI
 19 89570-85-4/BI
 3 90212-73-0/BI
 5 94835-69-5/BI
 20 96799-03-0/BI
 6 96799-04-1/BI
 15362 127464-60-2/BI
 3 306764-68-1/BI
 3 312501-62-5/BI
 3 331945-22-3/BI
 3 353771-45-6/BI
 104 64900-65-8/BI
 2259 66085-59-4/BI
 375926 7440-70-2/BI

L39

392992 (569655-94-3/BI OR 569655-95-4/BI OR 569655-96-5/BI OR 569655-97-6/BI OR 569655-98-7/BI OR 569655-99-8/BI OR 569656-00-4/BI OR 569656-01-5/BI OR 569656-02-6/BI OR 569656-03-7/BI OR 569656-04-8/BI OR 569656-05-9/BI OR 569656-06-0/BI OR 569656-07-1/BI OR 569656-08-2/BI OR 569656-09-3/BI OR 569656-10-6/BI OR 569656-11-7/BI OR 569656-12-8/BI OR 569656-13-9/BI OR 569656-14-0/BI OR 569656-15-1/BI OR 569656-16-2/BI OR 569656-17-3/BI OR 569656-18-4/BI OR 569656-19-5/BI OR 569656-20-8/BI OR 569656-21-9/BI OR 569656-22-0/BI OR 569656-23-1/BI OR 569656-24-2/BI OR 569656-25-3/BI OR 569656-26-4/BI OR 569656-27-5/BI OR 569656-28-6/BI OR 569656-29-7/BI OR 86358-85-2/BI OR 89570-85-4/BI OR 90212-73-0/BI OR 94835-69-5/BI OR 96799-03-0/BI OR 96799-04-1/BI OR 127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22-3/BI OR

353771-45-6/BI OR 64900-65-8/BI OR 66085-59-4/BI OR 7440-70-2/BI

=> s 139 or 138

L40 394405 L39 OR L38

=> s 140 and (cancer or tumor or cancer? or tumour or neoplastic or neoplasm?)

289571 CANCER

42241 CANCERS

300561 CANCER

(CANCER OR CANCERS)

381334 TUMOR

149800 TUMORS

428933 TUMOR

(TUMOR OR TUMORS)

304222 CANCER?

2925 TUMOUR

1107 TUMOURS

3972 TUMOUR

(TUMOUR OR TUMOURS)

55897 NEOPLASTIC

14 NEOPLASTICS

55907 NEOPLASTIC

(NEOPLASTIC OR NEOPLASTICS)

433581 NEOPLASM?

L41 16562 L40 AND (CANCER OR TUMOR OR CANCER? OR TUMOUR OR NEOPLASTIC OR NEOPLASM?)

=> e edg and 141

E1 2 EDFV/BI

E2 901 EDG/BI

E3 0 --> EDG AND L41/BI

E4 146 EDG1/BI

E5 1 EDG1C/BI

E6 113 EDG2/BI

E7 71 EDG3/BI

E8 1 EDG34/BI

E9 1 EDG3SB/BI

E10 61 EDG4/BI

E11 1 EDG4NON/BI

E12 56 EDG5/BI

=> s edg and 141

901 EDG

25 EDGS

916 EDG

(EDG OR EDGS)

L42 54 EDG AND L41

=> focus

PROCESSING COMPLETED FOR L42

L43 54 FOCUS L42 1-

=> d ibib abs hitstr 1-54

L43 ANSWER 1 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using **Edg** receptor modulators for
the treatment of **Edg** receptor-associated
conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
V.; Gluchowski, Charles

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	AA	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T2	20050707	JP 2003-562260	20030121
US 2005261298	A1	20051124	US 2003-390428	20030314
PRIORITY APPLN. INFO.:				
			US 2002-350445P	P 20020118
			US 2002-350446P	P 20020118
			US 2002-350447P	P 20020118
			US 2002-350448P	P 20020118
			WO 2003-US1881	W 20030121
			US 2003-352579	B2 20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an **Edg-2**, **Edg-3**, **Ed-4** or **Edg7** receptor-mediated biol. activity in a cell. A cell expressing the **Edg-2**, **Edg-3**, **Edg-4** or **Edg 7** receptor is contacted with a modulator of the **Edg-2**, **Edg-3**, **Ed-4** or **Edg 7** receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an **Edg-2**, **Edg-3**, **Ed-4** or **Edg-7** receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the **Edg-2**, **Edg-3**, **Ed-4** or **Edg7** receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT 182762-25-0, GenBank X83864 384729-36-6, GenBank U78192 385223-15-4, GenBank AF011466 390105-18-7, GenBank AF034780 390174-36-4, GenBank AF233365 390523-03-2, GenBank AF317676 392101-34-7, GenBank AF127138
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)
 RN 182762-25-0 CAPLUS
 CN DNA (human gene EDG-3 plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 384729-36-6 CAPLUS
 CN GenBank U78192 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 385223-15-4 CAPLUS
CN GenBank AF011466 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 390105-18-7 CAPLUS
CN GenBank AF034780 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 390174-36-4 CAPLUS
CN DNA (human gene CHEDG1 cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 390523-03-2 CAPLUS
CN GenBank AF317676 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 392101-34-7 CAPLUS
CN GenBank AF127138 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 353273-74-2P 569655-94-3P 569655-95-4P
569655-96-5P 569656-23-1P 569656-24-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(**Edg** receptor modulators for treatment of **Edg**
receptor-associated conditions)
RN 353273-74-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)- (9CI)
(CA INDEX NAME)




RN 569655-94-3 CAPLUS
CN 1,2,4-Triazin-3(2H)-one, 4,5-dihydro-5-(1H-indol-3-yl)-6-phenyl- (9CI)
(CA INDEX NAME)



RN 569655-95-4 CAPLUS
CN 1,2,4-Triazin-3(2H)-one, 4,5-dihydro-5-(1H-indol-3-yl)-6-phenyl-, (-)-
(9CI) (CA INDEX NAME)


Rotation (-).



RN 569655-96-5 CAPLUS

CN 1,2,4-Triazin-3(2H)-one, 4,5-dihydro-5-(1H-indol-3-yl)-6-phenyl-, (+)-
(9CI) (CA INDEX NAME)


Rotation (+).



RN 569656-23-1 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569656-24-2 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 94835-69-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Edg receptor modulators for treatment of Edg receptor-associated conditions)

RN 94835-69-5 CAPLUS

CN Butanamide, 4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



IT 40622-01-3P 173275-26-8P 304650-31-5P

311799-07-2P 312501-62-5P 312519-16-7P

331945-22-3P 334498-72-5P 342384-25-2P

353253-35-7P 353771-45-6P 355000-90-7P

569656-08-2P 569656-09-3P 569656-10-6P

569656-11-7P 569656-12-8P 569656-13-9P

569656-14-0P 569656-15-1P 569656-16-2P

569656-17-3P 569656-18-4P 569656-19-5P

569656-20-8P 569656-21-9P 569656-25-3P


569656-26-4P 569656-27-5P 569656-29-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Edg receptor modulators for treatment of Edg receptor-associated conditions)

RN 40622-01-3 CAPLUS


CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 173275-26-8 CAPLUS
 CN Phenol, 2-(1-ethyl-3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 304650-31-5 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2,6-dichlorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 311799-07-2 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chloro-6-fluorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 312501-62-5 CAPLUS
 CN 5-Thiazoleacetic acid, 4,5-dihydro-4-oxo-2-[(1-pentylhexylidene)hydrazino]- (9CI) (CA INDEX NAME)




RN 312519-16-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2,3-dichlorophenyl)-6-(trifluoromethyl)-
(9CI) (CA INDEX NAME)




RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 334498-72-5 CAPLUS

CN 3(2H)-Isoquinolinone, 1-(2,6-dichlorophenyl)-1,4-dihydro-6,7-dimethoxy-
(9CI) (CA INDEX NAME)




RN 342384-25-2 CAPLUS

CN 2H-Indol-2-one, 3-(2-amino-4-oxo-5(4H)-thiazolylidene)-1,3-dihydro-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 353253-35-7 CAPLUS

CN Acetic acid, [[2-[(4,5-diphenyl-2-thiazolyl)amino]-2-oxoethyl]thio]- (9CI)
(CA INDEX NAME)




RN 353771-45-6 CAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 355000-90-7 CAPLUS


CN 4-Quinolinecarboxamide, N-[(4-fluorophenyl)methyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 569656-08-2 CAPLUS
 CN Butanamide, N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)




RN 569656-09-3 CAPLUS
 CN Butanamide, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)




RN 569656-10-6 CAPLUS
 CN Butanamide, 4,4,4-trifluoro-N-[5-(4-fluorophenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)




RN 569656-11-7 CAPLUS
 CN Butanamide, 2-chloro-4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)-
 (9CI) (CA INDEX NAME)




RN 569656-12-8 CAPLUS
 CN Butanamide, N-[5-(3,5-dimethoxyphenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo-
 (9CI) (CA INDEX NAME)




RN 569656-13-9 CAPLUS
 CN Butanamide, 4,4,4-trifluoro-N-[5-(3-methoxyphenyl)-1H-pyrazol-3-yl]-3-oxo-
 (9CI) (CA INDEX NAME)



RN 569656-14-0 CAPLUS
 CN Butanamide, N-[5-(1,3-benzodioxol-5-yl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo-
 (9CI) (CA INDEX NAME)




RN 569656-15-1 CAPLUS
 CN Butanamide, 4,4,4-trifluoro-2-methyl-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)-
 (9CI) (CA INDEX NAME)




RN 569656-16-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-phenyl-N-2-propenyl-5-[(4,4,4-trifluoro-2-methyl-1,3-dioxobutyl)amino]- (9CI) (CA INDEX NAME)




RN 569656-17-3 CAPLUS

CN Butanamide, N-[5-(2-bromophenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)




RN 569656-18-4 CAPLUS

CN Butanamide, N-[5-(2,4-dimethoxyphenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)




RN 569656-19-5 CAPLUS


CN Butanamide, 4,4,4-trifluoro-3-oxo-N-[5-(2-thienyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 569656-20-8 CAPLUS
 CN Butanamide, 4,4,4-trifluoro-3-oxo-N-[5-(3-thienyl)-1H-pyrazol-3-yl]- (9CI)
 (CA INDEX NAME)




RN 569656-21-9 CAPLUS
 CN Butanamide, 4,4,4-trifluoro-3-oxo-N-[5-(4-pyridinyl)-1H-pyrazol-3-yl]-
 (9CI) (CA INDEX NAME)




RN 569656-25-3 CAPLUS
 CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-[(4-fluorophenyl)hydroxyamino]-
 , (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-26-4 CAPLUS
 CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3R,3aS,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569656-27-5 CAPLUS


CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-29-7 CAPLUS

CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)




IT 90212-73-0 107235-67-6 171286-07-0
 177360-28-0 306764-68-1 309282-30-2
 311773-65-6 312594-43-7 321679-76-9
 322662-05-5 327167-87-3 329350-38-1
 330630-42-7 331274-84-1 332161-39-4
 337349-59-4 337469-26-8 337498-14-3
 346699-98-7 353463-50-0 353793-15-4
 383164-60-1 389079-78-1 400064-03-1
 569655-97-6 569655-98-7 569656-22-0
 569656-28-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Edg receptor modulators for treatment of Edg receptor-associated conditions)


RN 90212-73-0 CAPLUS

CN s-Indacene-4-methanol, α -[(diethylamino)methyl]-1,2,3,5,6,7-hexahydro- (9CI) (CA INDEX NAME)




RN 107235-67-6 CAPLUS

CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-methylbutyl)- (9CI) (CA INDEX NAME)




RN 171286-07-0 CAPLUS

CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 177360-28-0 CAPLUS

CN 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 306764-68-1 CAPLUS


CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 309282-30-2 CAPLUS
 CN Spiro[3H-indole-3,2'-(3'H)-[1,3,4]thiadiazol]-2(1H)-one,
 5-methyl-5'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 311773-65-6 CAPLUS
 CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)



RN 312594-43-7 CAPLUS
 CN Benzoic acid, 2-[[[6-ethoxy-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 321679-76-9 CAPLUS
 CN Carbamic acid, [2-[(2,4,6-trimethylphenyl)amino]-1,3-benzodioxol-2-yl]-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 322662-05-5 CAPLUS

CN Benzaldehyde, 3-bromo-4-hydroxy-5-methoxy-, [4,6-bis(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)




RN 327167-87-3 CAPLUS

CN 3-Thiophenecarbonitrile, 4-amino-2-(ethylamino)-5-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)




RN 329350-38-1 CAPLUS

CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)




RN 330630-42-7 CAPLUS


CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)




RN 331274-84-1 CAPLUS
 CN Cyclopropanecarboxamide, N-(3-chloro-2-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 332161-39-4 CAPLUS
 CN Acetamide, 2-[[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 337349-59-4 CAPLUS
 CN Urea, N-[3-[[[(cyclohexylamino)carbonyl]amino]propyl]-N'-(2-methoxyphenyl)]-N-phenyl- (9CI) (CA INDEX NAME)




RN 337469-26-8 CAPLUS
 CN Ethanol, 2-[[[(7-chlorobenzo[b]thien-3-yl)methyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 337498-14-3 CAPLUS
 CN Acetamide, N-(2-ethylphenyl)-2-[[4-(4-methylphenyl)-1H-imidazol-2-yl]thio]-

(9CI) (CA INDEX NAME)




RN 346699-98-7 CAPLUS

CN Benzamide, 2,5-dichloro-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 353463-50-0 CAPLUS

CN Glycine, N-[[[3-cyano-4-(4-fluorophenyl)-6-phenyl-2-pyridinyl]thio]acetyl]- (9CI) (CA INDEX NAME)




RN 353793-15-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3-(hydroxyphenylamino)-1-(2-propoxyphenyl)- (9CI) (CA INDEX NAME)




RN 383164-60-1 CAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 4-[(2-hydroxyphenyl)amino]-6,6-dimethyl-2-oxo-3-(1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 389079-78-1 CAPLUS

CN 4-Quinolinecarboxamide, N-[(4-chlorophenyl)methyl]-3-methyl-2-phenyl-
(9CI) (CA INDEX NAME)




RN 400064-03-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 1-[2-(diethylamino)ethyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 569655-97-6 CAPLUS


CN Carbamic acid, (1H-benzimidazol-2-ylmethyl)-, (4-chloro-3-methylphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 569655-98-7 CAPLUS
 CN Piperazine, 1-(2,3-dichloro-6-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 569656-22-0 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dimethylphenyl)imino]-1,3-dihydro-1-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 569656-28-6 CAPLUS
 CN Thiourea, N-1,3-benzodioxol-5-yl-N'-(3,5-dichlorophenyl)-N-ethyl- (9CI) (CA INDEX NAME)




IT 406-00-8, 4-Fluorophenylhydroxylamine 434-75-3,
 2-Chloro-6-fluorobenzoic acid 4506-71-2 13100-05-5
 13380-67-1 19541-95-8 39151-19-4
 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 82799-44-8
 89570-85-4 96799-03-0 96799-04-1
 569656-04-8 569656-05-9 569656-06-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Edg receptor modulators for treatment of Edg
 receptor-associated conditions)
 RN 406-00-8 CAPLUS
 CN Benzenamine, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 434-75-3 CAPLUS
 CN Benzoic acid, 2-chloro-6-fluoro- (8CI, 9CI) (CA INDEX NAME)




RN 4506-71-2 CAPLUS
 CN Benzo[b]thiophene-3-carboxylic acid, 2-amino-4,5,6,7-tetrahydro-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 13100-05-5 CAPLUS
 CN 2-Propanone, 1-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 13380-67-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 1-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 19541-95-8 CAPLUS
 CN 1H-Pyrazol-3-amine, 5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 39151-19-4 CAPLUS
 CN Ethanone, 1-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 64900-65-8 CAPLUS
 CN Benzenesulfonyl isocyanate, 2-chloro- (9CI) (CA INDEX NAME)




RN 82799-44-8 CAPLUS
 CN 9H-Thioxanthen-9-one, 2,4-diethyl- (9CI) (CA INDEX NAME)




RN 89570-85-4 CAPLUS
 CN 2(1H)-Pyridinone, 5-(trifluoromethyl)-, hydrazone (9CI) (CA INDEX NAME)




RN 96799-03-0 CAPLUS
 CN 1H-Pyrazol-3-amine, 5-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 96799-04-1 CAPLUS
CN 1H-Pyrazol-3-amine, 5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 569656-04-8 CAPLUS
CN Benzoic acid, 2-[(2-formylphenyl)dithio]- (9CI) (CA INDEX NAME)



RN 569656-05-9 CAPLUS
CN Acetic-acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-06-0 CAPLUS
CN Hydrazinecarbothioamide, 2-(1-pentylhexylidene)- (9CI) (CA INDEX NAME)



IT 7741-54-0P 43071-45-0P 76293-13-5P
86358-85-2P 112612-58-5P 113054-02-7P


329069-72-9P 569655-99-8P 569656-00-4P
569656-01-5P 569656-02-6P 569656-03-7P
569656-07-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(**Edg** receptor modulators for treatment of **Edg**
receptor-associated conditions)


RN 7741-54-0 CAPLUS

CN 9H-Thioxanthen-9-one, 2,4-dimethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)




RN 43071-45-0 CAPLUS

CN 4-Quinolinecarboxylic acid, 3-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 76293-13-5 CAPLUS

CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 86358-85-2 CAPLUS

CN 2-Propanone, 1-[2-(benzoyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 112612-58-5 CAPLUS


CN Hydrazinecarbothioamide, 2-[(2,4-dimethoxyphenyl)methylene]- (9CI) (CA
INDEX NAME)




RN 113054-02-7 CAPLUS
 CN 2H-Indol-2-one, 3-(2-amino-4-oxo-5(4H)-thiazolylidene)-1,3-dihydro- (9CI)
 (CA INDEX NAME)




RN 329069-72-9 CAPLUS
 CN Hydrazinecarbothioamide, 2-[(3,5-dimethoxyphenyl)methylene]- (9CI) (CA
 INDEX NAME)



RN 569655-99-8 CAPLUS
 CN 1H-Pyrazol-3-amine, 5-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 569656-00-4 CAPLUS
 CN Acetamide, N-[5-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 569656-01-5 CAPLUS

CN Benzoic acid, 2-chloro-6-fluoro-, 2-[5-(trifluoromethyl)-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)




RN 569656-02-6 CAPLUS

CN Benzoic acid, 2,3-dichloro-, 2-[5-(trifluoromethyl)-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)




RN 569656-03-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 2-[5-(trifluoromethyl)-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)



RN 569656-07-1 CAPLUS

CN Benzenamine, N-[2-(4-methoxyphenyl)ethylidene]-, N-oxide (9CI) (CA INDEX NAME)



IT 7440-70-2, Calcium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; **Edg** receptor modulators for treatment of

Edg receptor-associated conditions)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg receptor modulators for treatment of
Edg receptor-associated conditions)
RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 2 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:259685 CAPLUS

DOCUMENT NUMBER: 142:309943

TITLE: Methods using Edg-2 receptor modulators for
treatment of edg-2 receptor-associated
conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 33 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2005065194	A1	20050324	US 2004-760061	20040116
PRIORITY APPLN. INFO.:			US 2003-440341P	P 20030116

OTHER SOURCE(S): MARPAT 142:309943

AB In one aspect, the invention provides a method for modulating an
Edg-2 receptor-mediated biol. activity in a cell. A cell
expressing the Edg-2 receptor is contacted with an modulator of
the Edg-2 receptor, which modulates the Edg-2 receptor
mediated biol. activity. In another aspect, the present invention
provides a method for modulating Edg-2 receptor mediated biol.
activity in a subject. A therapeutically effective amount of an modulator
of the Edg-2 receptor is administered to the subject. Comps.
of the invention include pyrrolidine-2,5-dione derivs. (preparation included).

IT 127464-60-2, VEGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-2 receptor modulators for treatment of edg-2
receptor-associated conditions)

RN 127464-60-2 CAPLUS


CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 94835-69-5
RL: PAC (Pharmacological activity); BIOL (Biological study)
(Edg-2 receptor modulators for treatment of edg-2
receptor-associated conditions)

RN 94835-69-5 CAPLUS

CN Butanamide, 4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)




IT 353273-74-2P 569656-23-1P 569656-24-2P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Edg-2 receptor modulators for treatment of edg-2 receptor-associated conditions)

RN 353273-74-2 CAPLUS


CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)- (9CI)
(CA INDEX NAME)



RN 569656-23-1 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569656-24-2 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 173275-26-8P 569656-25-3P 569656-26-4P


569656-27-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Edg-2 receptor modulators for treatment of edg-2 receptor-associated conditions)

RN 173275-26-8 CAPLUS


CN Phenol, 2-(1-ethyl-3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 569656-25-3 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-[(4-fluorophenyl)hydroxyamino]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569656-26-4 CAPLUS

CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3R,3aS,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569656-27-5 CAPLUS

CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 353793-15-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Edg-2 receptor modulators for treatment of edg-2 receptor-associated conditions)

RN 353793-15-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3-(hydroxyphenylamino)-1-(2-propoxyphenyl)- (9CI) (CA INDEX NAME)




IT 406-00-8, 4-Fluorophenylhydroxylamine 13380-67-1,

N-(4-Bromophenyl)maleimide


RL: RCT (Reactant); RACT (Reactant or reagent)

(Edg-2 receptor modulators for treatment of edg-2 receptor-associated conditions)


RN 406-00-8 CAPLUS
CN Benzenamine, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 13380-67-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 1-(4-bromophenyl)- (9CI) (CA INDEX NAME)



IT 13100-05-5P 86358-85-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(Edg-2 receptor modulators for treatment of edg-2
receptor-associated conditions)
RN 13100-05-5 CAPLUS
CN 2-Propanone, 1-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 86358-85-2 CAPLUS
CN 2-Propanone, 1-[2-(benzoyloxy)phenyl]- (9CI) (CA INDEX NAME)



IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; Edg-2 receptor modulators for treatment of
edg-2 receptor-associated conditions)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 3 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1242755 CAPLUS
DOCUMENT NUMBER: 143:472565
TITLE: Methods of treating conditions associated with an
Edg-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet
V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S.
Ser. No. 352,579.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261298	A1	20051124	US 2003-390428	20030314
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2002-350446P	P 20020118
			WO 2003-US1881	A1 20030121
			US 2003-352579	B2 20030127
			US 2002-350445P	P 20020118
			US 2002-350447P	P 20020118
			US 2002-350448P	P 20020118

OTHER SOURCE(S): MARPAT 143:472565

AB In one aspect, the present invention provides a method for modulating an **Edg-7** receptor mediated biol. activity in a cell. A cell expressing the **Edg-7** receptor is contacted with a modulator of the **Edg-7** receptor which is capable of modulating an **Edg-7** receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an **Edg-7** receptor mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the **Edg-7** receptor is administered to the subject.

IT 127464-60-2, VEGF

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**Edg-7** modulators for treating conditions associated with **Edg-7** receptor)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 40622-01-3P, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid
66085-59-4P 306764-68-1P 312501-62-5P
331945-22-3P 353771-45-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Edg-7 modulators for treating conditions associated with Edg-7 receptor)


RN 40622-01-3 CAPLUS

CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 66085-59-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 306764-68-1 CAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)




RN 312501-62-5 CAPLUS

CN 5-Thiazoleacetic acid, 4,5-dihydro-4-oxo-2-[(1-pentylhexylidene)hydrazino]- (9CI) (CA INDEX NAME)




RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 353771-45-6 CAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 4506-71-2, Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[B]thiophene-3-carboxylate 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 82799-44-8 569656-05-9 569656-06-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(Edg-7 modulators for treating conditions associated with Edg-7 receptor)





RN 4506-71-2 CAPLUS


CN Benzo[b]thiophene-3-carboxylic acid, 2-amino-4,5,6,7-tetrahydro-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 64900-65-8 CAPLUS

CN Benzenesulfonyl isocyanate, 2-chloro- (9CI) (CA INDEX NAME)






RN 76293-13-5 CAPLUS
 CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 569656-29-7 CAPLUS
 CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transport; **Edg**-7 modulators for treating conditions associated
 with **Edg**-7 receptor)
 RN 7440-70-2 CAPLUS
 CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 4 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:171122 CAPLUS
 DOCUMENT NUMBER: 138:335399
 TITLE: Biochemical regulation of breast **cancer** cell
 expression of S1P2 (**Edg**-5) and S1P3 (**Edg**-3) G protein-coupled receptors for
 sphingosine 1-phosphate
 AUTHOR(S): Dolezalova, Hana; Shankar, Geetha; Huang, Mei-Chuan;
 Bikle, Daniel D.; Goetzl, Edward J.
 CORPORATE SOURCE: Departments of Medicine and Microbiology-Immunology,
 University of California, San Francisco, CA,
 94143-0711, USA

SOURCE: Journal of Cellular Biochemistry (2003), 88(4), 732-743
 CODEN: JCEBD5; ISSN: 0730-2312
 PUBLISHER: Wiley-Liss, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB G protein-coupled receptors (GPCRs) for lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) transduce signals to many functions of normal cells. Most human **cancer** cells upregulates S1P and LPA GPCRs, in patterns distinctive for each type of **tumor**. The findings that 1-alpha, 25-dihydroxy-vitamin D3 (VD3) and all-trans retinoic acid (RA) differentially alter expression of the predominant S1P3 (**Edg-3**) R and S1P2 (**Edg-5**) R in human breast **cancer** cells (BCCs) permitted analyses of their individual activities, despite a lack of selective pharmacol. probes. S1P-evoked increases in [Ca2+]i in S1P3 R-predominant BCCs were suppressed by concns. of VD3 and RA which decreased expression of S1P3 Rs, despite RA-induced increases in S1P2 Rs. S1P-elicited chemokinetic migration of S1P3 R-predominant BCCs across a type IV collagen-coated micropore filter also was inhibited by concns. of VD3 and RA which decreased expression of S1P3 Rs. The RA-induced increase in expression of S1P2 Rs did not prevent suppression by RA of S1P-elicited chemokinesis, which appears to be mediated by S1P3 Rs, but instead exposed S1P2 R-mediated inhibition of epidermal growth factor-stimulated chemotaxis of BCCs. In contrast, expression of the predominant LPA2 Rs, LPA-evoked increase in [Ca2+]i and LPA-stimulated chemokinetic migration were suppressed concomitantly by RA but not VD3. Thus two structurally-homologous S1P Rs of BCCs differ in coupling to [Ca2+]i signaling and have opposite effects on protein growth factor-stimulated chemotaxis.

IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (two structurally-homologous S1P Rs of BCCs differ in coupling to [Ca2+]i signaling and have opposite effects on protein growth factor-stimulated chemotaxis)

RN 7440-70-2 CAPLUS
 CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 5 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:409218 CAPLUS
 DOCUMENT NUMBER: 142:441857
 TITLE: Methods of treating conditions associated with an **edg-2** receptor
 INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 347,420, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101518	A1	20050512	US 2003-390427	20030314

PRIORITY APPLN. INFO.:

US 2002-350448P

P 20020118


US 2003-347420

B2 20030117

OTHER SOURCE(S):

MARPAT 142:441857

GI



AB In one aspect, the present invention provides a method for modulating an **Edg-2** receptor mediated biol. activity in a cell. A cell expressing the **Edg-2** receptor is contacted with an modulator with formula I (where X = O, S; R20 = alkyl aryl, etc., R21 = alkyl, substituted alkyl, etc., R23 = H, alkyl, substituted alkyl; R24 = aryl, etc.) of the **Edg-2** receptor, which modulates the **Edg-2** receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating **Edg-2** receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg-2** receptor is administered to the subject.

IT 7440-70-2, Calcium, biological studies 127464-60-2,

Vascular endothelial growth factor

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(methods of treating conditions associated with an **edg-2** receptor)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 94835-69-5

RL: PAC (Pharmacological activity); BIOL (Biological study)

(methods of treating conditions associated with an **edg-2** receptor)

RN 94835-69-5 CAPLUS

CN Butanamide, 4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




IT 173275-26-8P 353273-74-2P 569656-26-4P
569656-27-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods of treating conditions associated with an **edg-2** receptor)


RN 173275-26-8 CAPLUS

CN Phenol, 2-(1-ethyl-3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 353273-74-2 CAPLUS


CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)- (9CI) (CA INDEX NAME)



RN 569656-26-4 CAPLUS

CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl) dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3R,3aS,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 569656-27-5 CAPLUS

CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl) dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 309282-30-2P 322662-05-5P 330630-42-7P
353793-15-4P 383164-60-1P 569656-23-1P
569656-24-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods of treating conditions associated with an **edg-2** receptor)


RN 309282-30-2 CAPLUS

CN Spiro[3H-indole-3,2'-(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-methyl-5'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 322662-05-5 CAPLUS

CN Benzaldehyde, 3-bromo-4-hydroxy-5-methoxy-, [4,6-bis(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)




RN 330630-42-7 CAPLUS

CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)




RN 353793-15-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3-(hydroxyphenylamino)-1-(2-propoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 383164-60-1 CAPLUS


CN 3-Cyclohexene-1-carboxylic acid, 4-[(2-hydroxyphenyl)amino]-6,6-dimethyl-2-oxo-3-(1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-23-1 CAPLUS


CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 569656-24-2 CAPLUS
 CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 406-00-8, 4-Fluorophenylhydroxylamine 86358-85-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (methods of treating conditions associated with an **edg**-2
 receptor)
 RN 406-00-8 CAPLUS
 CN Benzenamine, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 86358-85-2 CAPLUS
 CN 2-Propanone, 1-[2-(benzoyloxy)phenyl]- (9CI) (CA INDEX NAME)




IT 13100-05-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methods of treating conditions associated with an **edg-2** receptor)

RN 13100-05-5 CAPLUS

CN 2-Propanone, 1-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L43 ANSWER 6 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:703129 CAPLUS

DOCUMENT NUMBER: 141:218996

TITLE: Methods using **Edg-7** modulators for treating conditions associated with an **Edg-7** receptor

INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 27 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167192	A1	20040826	US 2004-760002	20040116
PRIORITY APPLN. INFO.:			US 2003-440321P	P 20030116
			US 2003-454881P	P 20030313

OTHER SOURCE(S): MARPAT 141:218996

AB The invention provides a method for modulating an **Edg-7** receptor mediated biol. activity in a cell. A cell expressing the **Edg-7** receptor is contacted with a modulator of the **Edg-7** receptor which is capable of modulating an **Edg-7** receptor-mediated biol. activity. The invention also provides a method for modulating an **Edg-7** receptor-mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the **Edg-7** receptor is administered to the subject. Preparation of e.g. 4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-ylidenemethyl]phenoxyacetic acid is described.


IT 312501-62-5P 331945-22-3P 353771-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(**Edg-7** modulators for treating conditions associated with an **Edg-7** receptor)


RN 312501-62-5 CAPLUS

CN 5-Thiazoleacetic acid, 4,5-dihydro-4-oxo-2-[(1-pentylhexylidene)hydrazino]- (9CI) (CA INDEX NAME)




RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 353771-45-6 CAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)




IT 569656-05-9 569656-06-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)


RN 569656-05-9 CAPLUS

CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-06-0 CAPLUS

CN Hydrazinecarbothioamide, 2-(1-pentylhexylidene)- (9CI) (CA INDEX NAME)



IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mobilization; **Edg**-7 modulators for treating conditions
 associated with an **Edg**-7 receptor)
 RN 7440-70-2 CAPLUS
 CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

IT 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synthesis; **Edg**-7 modulators for treating conditions associated
 with an **Edg**-7 receptor)
 RN 127464-60-2 CAPLUS
 CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 7 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:703126 CAPLUS
 DOCUMENT NUMBER: 141:200234
 TITLE: Methods of treating conditions associated with the
Edg-3 receptor
 INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet
 V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 24 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004167181	A1	20040826	US 2004-760003	20040116
PRIORITY APPLN. INFO.:			US 2003-440322P	P 20030116
			US 2003-454880P	P 20030313

OTHER SOURCE(S): MARPAT 141:200234
 AB The invention provides a method of inhibiting the **Edg**-3
 receptor-mediated biol. activity in a cell. A cell expressing the
Edg-3 receptor is contacted with an amount of an **Edg**-3
 receptor inhibitor sufficient to inhibit the **Edg**-3
 receptor-mediated biol. activity. Preferably, the inhibitor is not a
 phospholipid. Also the invention provides a method where an **Edg**-
 3 receptor-mediated biol. activity is inhibited in a subject. A
 therapeutically effective amount of an inhibitor of the **Edg**-3
 receptor is administered to the subject. Preferably, the inhibitor is not
 a phospholipid.

IT 7440-70-2, Calcium, biological studies 127464-60-2,
 Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)

(methods of treating conditions associated with **Edg-3** receptor)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 177360-28-0 332161-39-4 346699-98-7

355000-90-7 389079-78-1 569656-28-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(methods of treating conditions associated with **Edg-3** receptor)


RN 177360-28-0 CAPLUS

CN 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 332161-39-4 CAPLUS

CN Acetamide, 2-[[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)




RN 346699-98-7 CAPLUS

CN Benzamide, 2,5-dichloro-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 355000-90-7 CAPLUS

CN 4-Quinolinecarboxamide, N-[(4-fluorophenyl)methyl]-3-methyl-2-phenyl-
(9CI) (CA INDEX NAME)




RN 389079-78-1 CAPLUS

CN 4-Quinolinecarboxamide, N-[(4-chlorophenyl)methyl]-3-methyl-2-phenyl-
(9CI) (CA INDEX NAME)



RN 569656-28-6 CAPLUS

CN Thiourea, N-1,3-benzodioxol-5-yl-N'-(3,5-dichlorophenyl)-N-ethyl- (9CI)
(CA INDEX NAME)




IT 4506-71-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(methods of treating conditions associated with **Edg-3** receptor)

RN 4506-71-2 CAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 2-amino-4,5,6,7-tetrahydro-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



L43 ANSWER 8 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:80878 CAPLUS

DOCUMENT NUMBER: 140:139547

TITLE: Screening for substituted aryl isoxazole effectors of the **Edg-1** receptor for the treatment of receptor-associated conditions

INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Gluchowski, Charles; Spencer, Juliet V.

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009816	A1	20040129	WO 2003-US22463	20030717
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2466288	AA	20040129	CA 2003-2466288	20030717
AU 2003252023	A1	20040209	AU 2003-252023	20030717
US 2004147562	A1	20040729	US 2003-621966	20030717
EP 1523556	A1	20050420	EP 2003-765716	20030717
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005533852	T2	20051110	JP 2004-523557	20030717
PRIORITY APPLN. INFO.:			US 2002-397299P	P 20020718
			WO 2003-US22463	W 20030717

OTHER SOURCE(S): MARPAT 140:139547

AB In one aspect, the present invention provides a method of modulating an **Edg-1** receptor mediated biol. activity in a cell. A cell expressing the **Edg-1** receptor is contacted with a modulator of the **Edg-1** receptor sufficient to modulate the **Edg-1** receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an **Edg-1** receptor mediated biol. activity in a subject. A therapeutically effective amount of

a modulator of the **Edg-1** receptor is administered to the subject.

IT 182762-25-0, GenBank X83864 384729-36-6, GenBank U78192
385223-15-4, GenBank AF011466 390105-18-7, GenBank
AF034780 390174-36-4, GenBank AF233365 390523-03-2,
GenBank AF317676 392101-34-7, GenBank AF127138
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(screening for substituted aryl isoxazole effectors of **Edg-1**
receptor for treatment of receptor-associated conditions)
RN 182762-25-0 CAPLUS
CN DNA (human gene EDG-3 plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 384729-36-6 CAPLUS
CN GenBank U78192 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 385223-15-4 CAPLUS
CN GenBank AF011466 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390105-18-7 CAPLUS
CN GenBank AF034780 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390174-36-4 CAPLUS
CN DNA (human gene CHEDG1 cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390523-03-2 CAPLUS
CN GenBank AF317676 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 392101-34-7 CAPLUS
CN GenBank AF127138 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 9 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:612479 CAPLUS
DOCUMENT NUMBER: 141:138524
TITLE: Gene expression profiles and microarrays for colon
cancer and their use for **cancer**
diagnosis and therapeutics
INVENTOR(S): Eveleigh, Deepa; Bigwood, Douglas; Taylor, Ian
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004146921	A1	20040729	US 2004-764425	20040123
CA 2514187	AA	20040812	CA 2004-2514187	20040123
WO 2004066941	A2	20040812	WO 2004-US2188	20040123
WO 2004066941	A3	20060803		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM,
 GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW,
 MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 EP 1603514 A2 20051214 EP 2004-704977 20040123
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: US 2003-442582P P 20030124
 WO 2004-US2188 W 20040123

AB The present invention relates to gene expression profiles for colon
cancer, microarrays comprising nucleic acid sequences representing
 gene expression profiles, and methods of using the expression profiles and
 microarrays. The invention also provides methods and compns. for
 diagnostic assays for detecting **cancer** and therapeutic methods
 and compns. for treating **cancer**. The invention also provides
 methods for designing, identifying, and optimizing therapeutics for
cancer. [The present invention claims a total of 96 nucleic acid
 sequences and 95 protein sequences and provides their GenBank or RefSeq
 accession nos., but the Sequence Listing was not made available on
 publication of the patent application.].

IT **127464-60-2**, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP
 (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (gene expression profiles and microarrays for colon **cancer**
 and their use for **cancer** diagnosis and therapeutics)

RN **127464-60-2** CAPLUS
 CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:703127 CAPLUS
 DOCUMENT NUMBER: 141:200235
 TITLE: Methods of treating conditions associated with an
Edg-3 receptor
 INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
 V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167185	A1	20040826	US 2004-760064	20040116
PRIORITY APPLN. INFO.:			US 2003-440325P	P 20030116
OTHER SOURCE(S):	MARPAT 141:200235			

AB The invention provides a method of inhibiting the **Edg-3** receptor
 - mediated biol. activity in a cell. A cell expressing the **Edg**
 -3 receptor is contacted with an amount of an **Edg-3** receptor
 inhibitor sufficient to inhibit the **Edg-3** receptor - mediated
 biol. activity. Preferably, the inhibitor is not a phospholipid. Also
 the invention provides a method where an **Edg-3** receptor -
 mediated biol. activity is inhibited in a subject. A therapeutically
 effective amount of an inhibitor of the **Edg-3** receptor is

administered to the subject. Preferably, the inhibitor is not a phospholipid.


IT 7440-70-2, Calcium, biological studies 127464-60-2,
Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of treating conditions associated with **Edg**-3 receptor)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca


RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 107235-67-6 171286-07-0 311773-65-6
329350-38-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(methods of treating conditions associated with **Edg**-3 receptor)
RN 107235-67-6 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-methylbutyl)- (9CI) (CA INDEX NAME)




RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 311773-65-6 CAPLUS
CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)



RN 329350-38-1 CAPLUS
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester
(9CI) (CA INDEX NAME)



L43 ANSWER 11 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703122 CAPLUS
DOCUMENT NUMBER: 141:200233
TITLE: Methods of treating conditions associated with an
Edg-2 receptor
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167132	A1	20040826	US 2004-760063	20040116
PRIORITY APPLN. INFO.:			US 2003-440337P	P 20030116
OTHER SOURCE(S):	MARPAT 141:200233			

AB The invention provides a method for modulating an **Edg-2** receptor-mediated biol. activity in a cell. A cell expressing the **Edg-2** receptor is contacted with an modulator of the **Edg-2** receptor, which modulates the **Edg-2** receptor mediated biol. activity. In another aspect, the invention provides a method for modulating **Edg-2** receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg-2** receptor is administered to the subject.

IT **7440-70-2**, Calcium, biological studies **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study) (methods of treating conditions associated with an **Edg-2** receptor)

RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **384729-36-6**, GenBank U78192

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(methods of treating conditions associated with an **Edg-2**
receptor)

RN 384729-36-6 CAPLUS

CN GenBank U78192 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 322662-05-5 330630-42-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(methods of treating conditions associated with an **Edg-2**
receptor)


RN 322662-05-5 CAPLUS

CN Benzaldehyde, 3-bromo-4-hydroxy-5-methoxy-, [4,6-bis(phenylamino)-1,3,5-
triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



RN 330630-42-7 CAPLUS

CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-
1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



L43 ANSWER 12 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:803937 CAPLUS

DOCUMENT NUMBER: 141:307509

TITLE: Methods of treating conditions associated with an
Edg-2 receptor

INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet
V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004192739	A1	20040930	US 2004-759992	20040116
PRIORITY APPLN. INFO.:			US 2003-440340P	P 20030116
			US 2003-455112P	P 20030313

OTHER SOURCE(S): MARPAT 141:307509

AB In one aspect, the present invention provides a method for modulating an **Edg-2** receptor mediated biol. activity in a cell. A cell expressing the **Edg-2** receptor is contacted with an modulator of the **Edg-2** receptor, which modulates the **Edg-2** receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating **Edg-2** receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg-2** receptor is administered to the subject.

IT **7440-70-2**, Calcium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (treating conditions associated with **Edg-2** receptor)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

IT **127464-60-2**, Vascular endothelial growth factor

RL: BSU (Biological study, unclassified); BIOL (Biological study) (treating conditions associated with **Edg-2** receptor)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT **309282-30-2 383164-60-1**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treating conditions associated with **Edg-2** receptor)


RN 309282-30-2 CAPLUS

CN Spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-methyl-5'-(4-methylphenyl)- (9CI) (CA INDEX NAME)





RN 383164-60-1 CAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 4-[(2-hydroxyphenyl)amino]-6,6-dimethyl-2-oxo-3-(1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)



L43 ANSWER 13 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:703124 CAPLUS
 DOCUMENT NUMBER: 141:218944
 TITLE: Treating conditions associated with an **Edg-7** receptor
 INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 29 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167165	A1	20040826	US 2004-760062	20040116
PRIORITY APPLN. INFO.:			US 2003-440336P	P 20030116
OTHER SOURCE(S):	MARPAT 141:218944			
GI				




AB The invention provides a method for modulating an **Edg-7** receptor mediated biol. activity in a cell. A cell expressing the **Edg-7** receptor is contacted with a modulator of the **Edg-7** receptor which is capable of modulating an **Edg-7** receptor mediated biol. activity. The invention provides a method for modulating an **Edg-7** receptor mediated biol. activity in a subject. A therapeutically effective amount of the **Edg-7** receptor modulator with formula I (where R1, R2 R3 R4 and R7 = -H, -halo, -CN, -NO2 etc. independently) or with formula II (where R1, R2, R3, R4 and R7 = -H, -halo, -NO2 -CN, etc.) or a pharmaceutically available solvate or hydrate thereof is administered to the subject.

IT **127464-60-2**, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (methods of treating conditions associated with an **Edg-7** receptor)
 RN 127464-60-2 CAPLUS
 CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)


IT 40622-01-3P 66085-59-4P 306764-68-1P
569656-29-7P

(methods of treating conditions associated with an **Edg-7** receptor)


CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-
, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)




CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



IT **76293-13-5P**, 2,4-Dimethylthioxanthen-9-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (methods of treating conditions associated with an **Edg-7**
 receptor)
 RN 76293-13-5 CAPLUS
 CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **7440-70-2**, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transport; methods of treating conditions associated with an **Edg**
 -7 receptor)
 RN 7440-70-2 CAPLUS
 CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 14 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:320060 CAPLUS
 DOCUMENT NUMBER: 134:339179
 TITLE: Nucleic acids and proteins associated with
cancer as antitumor targets
 INVENTOR(S): Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David
 PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030964	A2	20010503	WO 2000-US29126	20001020
WO 2001030964	A3	20010809		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001013397 A5 20010508 AU 2001-13397 20001020
PRIORITY APPLN. INFO.: US 1999-161232P P 19991022
US 2000-693783 A 20001019
WO 2000-US29126 W 20001020

AB This invention relates to the discovery of nucleic acids associated with cell proliferation, neoplasia, cell transformation, malignant **tumor** formation and metastasis and uses therefor. The present invention provides a method for **cancer** diagnosing by detecting the overexpression or the underexpression of a **cancer**-associated mRNA in the tissue of interest, preferably in liver, breast, prostate, kidney and colon. In another aspect, the invention provides methods for arresting **cancer** and a method for identifying a modulators of **cancer** development.

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heparin binding, gene for; nucleic acids and proteins associated with **cancer** as antitumor targets)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 15 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:158474 CAPLUS

DOCUMENT NUMBER: 142:254569

TITLE: Derivatives of cyclic quinone that regulate gene expression for use in prevention or therapy of human diseases

INVENTOR(S): Padia, Janak K.; O'Brien, Sean; Lu, Jiemin; Pikul, Stanislaw

PATENT ASSIGNEE(S): Avalon Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016000	A1	20050224	WO 2004-US25038	20040803
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-492653P P 20030805

OTHER SOURCE(S): MARPAT 142:254569

AB This invention relates to production of cyclic quinone derivs. for use in regulation of gene expression, as relates to prevention or therapy of

human diseases. Cyclic quinone synthesis schemes and structures are presented. With the goal of transcription regulation in diseased tissues, gene expression profile data is provided. The intended disease target for this invention is adenocarcinoma of the colon, however the invention claims application in numerous human diseases. Applications of the invention include production of cyclic quinone-based active ingredients in therapeutic agents.

IT 127464-60-2, VEGF

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(derivs. of cyclic quinone that regulate gene expression for use in prevention or therapy of human diseases)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 16 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:248644 CAPLUS

DOCUMENT NUMBER: 142:274057

TITLE: Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy

INVENTOR(S): Liew, Choong-chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241727	A1	20041202	US 2004-812731	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241727	A1	20041202	US 2004-812731	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812731	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 385223-15-4, GenBank AF011466

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; sequences of human schizophrenia-related genes
and use for diagnosis, prognosis and therapy)

RN 385223-15-4 CAPLUS

CN GenBank AF011466 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 17 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:287092 CAPLUS

DOCUMENT NUMBER: 136:384733

TITLE: Sphingosine 1-phosphate induces chemotaxis of immature dendritic cells and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses

AUTHOR(S): Idzko, Marco; Panther, Elisabeth; Corinti, Silvia; Morelli, Anna; Ferrari, Davide; Herouy, Yared; Dichmann, Stefan; Mockenhaupt, Maja; Gebicke-Haerter, Peter; Di Virgilio, Francesco; Girolimoni, Giampiero; Norgauer, Johannes

CORPORATE SOURCE: Department of Experimental Dermatology, Freiburg, Germany

SOURCE: FASEB Journal (2002), 16(6), 625-627, 10.1096/fj.01-0625fje

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sphingosine 1-phosphate (S1P) is a potent extracellular lysolipid phosphoric acid mediator that is released after IgE-stimulation of mast cells. Here we investigated the biol. activity and intracellular signaling of S1P on human dendritic cells (DC), which are specialized antigen presenting cells with the ability to migrate into peripheral tissues and lymph nodes, as well as control the activation of naive T cells. We show that immature and mature DC express the mRNA for different S1P receptors, such as endothelial differentiation gene (EDG)-1, EDG-3, EDG-5, and EDG-6. In immature DC, S1P stimulated pertussis toxin-sensitive Ca²⁺ increase actin-polymerization and chemotaxis. These responses were lost by DC matured with lipopolysaccharide. In maturing DC, however, S1P inhibited the secretion of tumor necrosis factor- α and interleukin (IL)-12, whereas it enhanced secretion of IL-10. As a consequence, mature DC exposed to S1P showed a reduced and increased capacity to generate allogeneic Th1 and Th2 responses, resp. In summary, our study implicates that S1P might regulate the trafficking of DC and ultimately favor Th2 lymphocyte-dominated immunity.

IT 7440-70-2, Calcium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sphingosine 1-phosphate induces chemotaxis of immature dendritic cells and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:394682 CAPLUS

DOCUMENT NUMBER: 142:445550
 TITLE: Gene expression profiles for the diagnosis and prognosis of breast **cancer**
 INVENTOR(S): Erlander, Mark; Ma, Xiao-Jun; Wang, Wei; Wittliff, James L.
 PATENT ASSIGNEE(S): Arcturus Bioscience, Inc. University of Louisville, USA
 SOURCE: U.S. Pat. Appl. Publ., 40 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005095607	A1	20050505	US 2004-795092	20040305
WO 2005098037	A1	20051020	WO 2004-US6760	20040305
WO 2005098037	C1	20060209		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1651772 A1 20060503 EP 2004-718019 20040305

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-453006P P 20030307
 WO 2004-US6760 W 20040305

AB The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast **cancer** patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast **cancer** survival.

IT 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
 (gene for, in breast **cancer** diagnosis; gene expression profiles for diagnosis and prognosis of breast **cancer**)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 19 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:807997 CAPLUS
 DOCUMENT NUMBER: 140:126171
 TITLE: Genes commonly upregulated by hypoxia in human breast **cancer** cells MCF-7 and MDA-MB-231
 AUTHOR(S): Bando, Hiroko; Toi, Masakazu; Kitada, Kunio; Koike, Morio
 CORPORATE SOURCE: Breast Cancer Research Group, Tokyo Metropolitan Cancer and Infectious Diseases Center, Bunkyo-ku, Tokyo, 113-0087, Japan
 SOURCE: Biomedicine & Pharmacotherapy (2003), 57(8), 333-340

CODEN: BIPHEX; ISSN: 0753-3322

PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Hypoxia is a stress that causes alterations in signal transduction and gene instability. In the **cancer** microenvironment, hypoxia plays a significant role in forming a **tumor** phenotype and **tumor** progression. We aimed to identify the genes upregulated by hypoxia in human breast **cancer** cell lines, a hormone-dependent MCF-7 and a hormone-independent MDA-MB-231, using microarray anal. These cells were exposed to two oxygen concns. such as 21% and 1% in a time-course. Out of 12,625 genes, 26 genes were identified as commonly upregulated in both MCF-7 and MDA-MB-231 cells. Some of these genes were already reported as hypoxia-related, but some of those were identified newly. These commonly upregulated genes between hormone-dependent and hormone-independent cells would be a clue to study hypoxia-related events and to explore the novel therapeutic targets in human breast **cancer**.

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene commonly upregulated by hypoxia in human breast **cancer**)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:634161 CAPLUS

DOCUMENT NUMBER: 141:167758

TITLE: Sequences of apoptosis-associated protein kinases and G protein-coupled receptors, and use in **cancer** diagnosis, therapy, and drug screening

INVENTOR(S): Seery, Liam; Hayes, Ian; Murphy, Finbarr

PATENT ASSIGNEE(S): Eirx Therapeutics Limited, Ire.

SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065959	A2	20040805	WO 2004-GB271	20040123
WO 2004065959	A3	20041125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ			
AU 2004205785	A1	20040805	AU 2004-205785	20040123
CA 2513148	AA	20040805	CA 2004-2513148	20040123
EP 1588163	A2	20051026	EP 2004-704638	20040123
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006518590	T2	20060817	JP 2006-500235	20040123
PRIORITY APPLN. INFO.:			GB 2003-1566	A 20030123
			US 2003-457533P	P 20030325
			WO 2004-GB271	W 20040123

AB The present invention identifies a number of genes, "apoptosis-associated" genes, whose expression is correlated with an early stage in the regulation of apoptosis. The identification and role of these genes in

apoptosis is validated using model assays and by knocking down gene expression using RNAi and assessing the resultant phenotype for altered apoptosis progression. Accordingly, these genes represent new targets for therapeutic targets. Methods are provided for identifying agents that modulate the function of an apoptosis-associated polypeptide or expression of nucleic acids encoding the apoptosis-associated polypeptide, as well as detecting the presence of an apoptosis-associated polypeptide in a sample using hybridization-based levels of gene expression or antibody binding.

IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequences of apoptosis-associated protein kinases and G protein-coupled receptors, and use in **cancer** diagnosis, therapy, and drug screening)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:925904 CAPLUS

DOCUMENT NUMBER: 141:393465

TITLE: Genes showing altered expression in lung
cancer and their products and their use in
diagnosis and treatment

INVENTOR(S): Mennerich, Detlev; Bruemmendorf, Thomas; Heiden
Castanos-Velez, Esmeralda; Hermann, Klaus; Kinnemann,
Henrik; Li, Xinzhong; Roepcke, Stefan; Staub, Eike;
Hinzmann, Bernd; Rosenthal, Andre; Pilarsky, Christian
PATENT ASSIGNEE(S): Germany

SOURCE: Ger. Offen., 1381 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10316701	A1	20041104	DE 2003-10316701	20030409
EP 1498424	A2	20050119	EP 2004-90140	20040408
EP 1498424	A3	20050525		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: DE 2003-10316701 A 20030409

AB Genes showing altered levels of expression in human bronchial carcinoma are identified for use in the diagnosis or treatment of the disease. Expression of the gene or presence of the gene product may be used as a diagnostic marker and either the gene or its product may be a target for antineoplastic drugs. Microarray anal. identified 489 genes showing altered patterns of expression in patients with lung adenocarcinoma or squamous cell carcinoma.

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene for, altered expression in bronchial carcinoma; genes showing altered expression in lung **cancer** and their products and their use in diagnosis and treatment)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:587551 CAPLUS

DOCUMENT NUMBER: 135:302740

TITLE: Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma

AUTHOR(S): Ammit, Alain J.; Hastie, Annette T.; Edsall, Lisa C.; Hoffman, Rebecca K.; Amrani, Yassine; Krymskaya, Vera P.; Kane, Sibyl A.; Peters, Stephen P.; Penn, Raymond B.; Spiegel, Sarah; Panettieri, Reynold A., Jr.

CORPORATE SOURCE: Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

SOURCE: FASEB Journal (2001), 15(7), 1212-1214, 10.1096/fj.00-0742fje

CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Asthma is characterized by airway inflammation, remodeling, and hyperresponsiveness to contractile stimuli that promote airway constriction and wheezing. Here we present evidence that sphingosine 1-phosphate (SPP) is a potentially important inflammatory mediator implicated in the pathogenesis of airway inflammation and asthma. SPP levels were elevated in the airways of asthmatic (but not control) subjects following segmental antigen challenge, and this increase was correlated with a concomitant increase in airway inflammation. Because human airway smooth muscle (ASM) cells expressed **EDG** receptors for SPP (**EDG**-1, -3, -5, and -6), we examined whether SPP may play a role in airway inflammation and remodeling, by affecting ASM cell growth, contraction, and cytokine secretion. SPP is mitogenic and augments EGF- and thrombin-induced DNA proliferation by increasing G1/S progression. SPP increased phosphoinositide turnover and intracellular calcium mobilization, the acute signaling events that affect ASM contraction. By modulating adenylate cyclase activity and cAMP accumulation, SPP had potent effects on cytokine secretion. Although SPP inhibited TNF- α -induced RANTES release, it induced substantial IL-6 secretion alone and augmented production of IL-6 induced by TNF- α . These studies are the first to associate SPP with airway inflammation and to identify SPP as an effective regulator of ASM growth, contraction and synthetic functions.

IT 7440-70-2, Calcium, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(transport; sphingosine 1-phosphate in **EDG** receptor-mediated modulating human airway smooth muscle cell growth, contraction and cAMP-dependent cytokine secretion promoting inflammation and airway remodeling in asthma in relation to)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:795460 CAPLUS

DOCUMENT NUMBER: 137:309424
 TITLE: The influence of lysophosphatidic acid on the functions of human dendritic cells
 AUTHOR(S): Panther, Elisabeth; Idzko, Marco; Corinti, Silvia; Ferrari, Davide; Herouy, Yared; Mockenhaupt, Maja; Dichmann, Stefan; Gebicke-Haerter, Peter; Di Virgilio, Francesco; Girolomoni, Giampiero; Norgauer, Johannes
 CORPORATE SOURCE: Department of Experimental Dermatology, University of Freiburg, Freiburg, D-79104, Germany
 SOURCE: Journal of Immunology (2002), 169(8), 4129-4135
 CODEN: JOIMA3; ISSN: 0022-1767
 PUBLISHER: American Association of Immunologists
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Lysophosphatidic acid (LPA) is a bioactive lipid mediator which is generated by secretory phospholipase A2. In this study, the authors studied the biol. activity of LPA on human dendritic cells (DCs), which are specialized APCs characterized by their ability to migrate into target sites and secondary lymphoid organs to process Ags and activate naive T cells. The authors show that immature and mature DCs express the mRNA for different LPA receptors such as endothelial differentiation gene (EDG)-2, EDG-4, and EDG-7. In immature DCs, LPA stimulated pertussis toxin-sensitive Ca²⁺ increase, actin polymerization, and chemotaxis. During the maturation process, DCs lost their ability to respond toward LPA with Ca²⁺ transients, actin polymerization, and chemotaxis. However, LPA inhibited in a pertussis toxin-insensitive manner the secretion of IL-12 and TNF α as well as enhanced secretion of IL-10 from mature DCs. Moreover, LPA did not affect the endocytic or phagocytic capacities and the surface phenotype of DCs, although it increased the allostimulatory function of mature DC and inhibited their capacity to induce Th1 differentiation. In summary, the authors' study implicates that LPA might regulate the trafficking, cytokine production, and T cell-activating functions of DCs.

IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (influence of lysophosphatidic acid on functions of human dendritic cells)
 RN 7440-70-2 CAPLUS
 CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:612542 CAPLUS
 DOCUMENT NUMBER: 143:114060
 TITLE: Highly active lysophosphatidic acids and antibodies for disease diagnosis and therapy and drug screening
 INVENTOR(S): Hayashi, Akio; Nakade, Shinji; Suzuki, Hidehiro
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005064332	A1	20050714	WO 2004-JP19241	20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2003-432844 A 20031226
JP 2004-224351 A 20040730

OTHER SOURCE(S): MARPAT 143:114060

AB The invention provides a method of screening a preventive and/or therapeutic substance for diseases in which LPA takes part. The compds. obtained by this screening method or with the use of relevant screening kit, their salts or solvates and prodrugs thereof would modulate the binding of highly active LPA with LPA receptor in human and other mammals, so that they can be used as a preventive and/or therapeutic agent for diseases in which LPA takes part, for example, urinary diseases, central diseases, inflammatory diseases, circulatory diseases, **cancer**, diabetes, immune system disorders and alimentary diseases.

IT **7440-70-2**, Calcium, biological studies
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study) (intracellular concentration; highly active lysophosphatidic acids and antibodies for drug screening and diagnosis and therapy of urinary, CNS, inflammatory, circulatory, immune and **neoplastic** disease)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1291789 CAPLUS

DOCUMENT NUMBER: 144:46156

TITLE: Differential expression of molecules associated with acute stroke

INVENTOR(S): Baird, Alison E.; Moore, David F.; Goldin, Ehud

PATENT ASSIGNEE(S): United States Dept. of Health, USA

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116268	A2	20051208	WO 2005-US18744	20050527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

US 2006046259 A1 20060302 US 2005-155835 20050617
PRIORITY APPLN. INFO.: US 2004-575279P P 20040527
WO 2005-US18744 A2 20050527

AB Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely

neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment.

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(differential expression of mols. associated with acute stroke)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:21952 CAPLUS

DOCUMENT NUMBER: 144:485756

TITLE: Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites

AUTHOR(S): Sako, Akihiro; Kitayama, Joji; Shida, Dai; Suzuki, Rika; Sakai, Teruyuki; Ohta, Hideo; Nagawa, Hirokazu
CORPORATE SOURCE: Department of Surgical Oncology, University of Tokyo, Japan

SOURCE: Journal of Surgical Research (2006), 130(1), 94-101
CODEN: JSGRA2; ISSN: 0022-4804

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: Lysophosphatidic acid (LPA) is a lipid mediator with multiple biological activities that may affect the progression of various **cancers**. Malignant ascites contains high levels of LPA as well as vascular endothelial growth factor (VEGF). Although LPA receptors are widely expressed in normal as well as **cancer** cells, little is known about the effect of LPA on host cells. Therefore, we evaluated the effect of LPA specifically on peritoneal mesothelial cells (PMC), and assessed another aspect of LPA in **tumor** biological mediated through the host cells. Materials and methods: The effect of LPA on the production of VEGF was evaluated by ELISA and northern blotting. Next, we quantified human- and mouse-VEGF separately in ascitic fluid of nude mice inoculated *i.p.* with a human gastric **cancer**, MKN45, and thus evaluated the ratio of host-derived VEGF in malignant ascites. Results: Addition of 10 to 80 μ M LPA enhanced VEGF production by PMC through gene activation. The effect was strongly inhibited by pre-treatment with PTX or K16425, indicating

that the effect was mainly dependent on the LPA1 signal. Of the VEGF in ascitic fluid at 3 wk after **tumor** inoculation, 12.8% was derived from mouse cells. At 6 wk, however, the ratio of host-derived VEGF was reduced to 5.0%, suggesting that the ratio of host-derived VEGF may be higher in the earlier phase. Conclusion: Because **tumor** growth is often associated with an increase of LPA concentration in ascites, stimulation of VEGF production in PMC might have an important role in the growth of **cancer** cells disseminated in the peritoneal cavity.

IT 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (lysophosphatidic acid enhanced vascular endothelial growth factor production in human PMC and reduced mouse and human-derived VEGF in ascitic fluid of mouse model inoculated i.p. with human gastric **cancer** cell line MKN45)

RN 127464-60-2 CAPLUS
 CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:112850 CAPLUS

DOCUMENT NUMBER: 142:153469

TITLE: Gene expression profiles and biomarkers for the detection of lung disease-related and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 47

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241728	A1	20041202	US 2004-812764	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812764	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder **cancer**, rheumatoid arthritis, osteoarthritis, liver **cancer**, schizophrenia, Chagas

disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **385223-15-4**, GenBank AF011466
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

E1	1	108-31-6/BI
E2	1	108-38-3/BI
E3	1	119-80-2/BI
E4	1	1226-42-2/BI
E5	1	127464-60-2/BI
E6	1	306764-68-1/BI
E7	1	312501-62-5/BI
E8	1	331945-22-3/BI
E9	1	353771-45-6/BI
E10	1	40622-01-3/BI
E11	1	4506-71-2/BI
E12	1	5242-26-2/BI
E13	1	569656-05-9/BI
E14	1	569656-06-0/BI
E15	1	569656-29-7/BI
E16	1	60-92-4/BI
E17	1	619-05-6/BI
E18	1	64900-65-8/BI
E19	1	66085-59-4/BI
E20	1	7440-70-2/BI
E21	1	76293-13-5/BI
E22	1	7741-54-0/BI
E23	1	82799-44-8/BI
E24	1	91-56-5/BI
E25	1	108-31-6/BI
E26	1	108-38-3/BI
E27	1	119-80-2/BI
E28	1	1226-42-2/BI
E29	1	127464-60-2/BI
E30	1	306764-68-1/BI
E31	1	312501-62-5/BI
E32	1	331945-22-3/BI
E33	1	353771-45-6/BI
E34	1	40622-01-3/BI
E35	1	4506-71-2/BI
E36	1	5242-26-2/BI
E37	1	569656-05-9/BI
E38	1	569656-06-0/BI
E39	1	569656-29-7/BI
E40	1	60-92-4/BI
E41	1	619-05-6/BI
E42	1	64900-65-8/BI
E43	1	66085-59-4/BI
E44	1	7440-70-2/BI
E45	1	76293-13-5/BI
E46	1	7741-54-0/BI
E47	1	82799-44-8/BI
E48	1	91-56-5/BI
E49	1	100-65-2/BI
E50	1	107235-67-6/BI
E51	1	108-31-6/BI
E52	1	108-38-3/BI
E53	1	112612-58-5/BI
E54	1	113054-02-7/BI
E55	1	120-72-9/BI
E56	1	1226-42-2/BI
E57	1	123-11-5/BI
E58	1	127464-60-2/BI
E59	1	13100-05-5/BI
E60	1	13380-67-1/BI
E61	1	136382-28-0/BI
E62	1	140-75-0/BI

E63	1	1468-83-3/BI
E64	1	1476-23-9/BI
E65	1	149246-80-0/BI
E66	1	149246-86-6/BI
E67	1	1572-10-7/BI
E68	1	171286-07-0/BI
E69	1	173275-26-8/BI
E70	1	177360-28-0/BI
E71	1	182762-25-0/BI
E72	1	19541-95-8/BI
E73	1	208519-10-2/BI
E74	1	208519-15-7/BI
E75	1	218763-60-1/BI
E76	1	23448-86-4/BI
E77	1	23821-37-6/BI
E78	1	259476-69-2/BI
E79	1	262400-57-7/BI
E80	1	2642-63-9/BI
E81	1	26993-30-6/BI
E82	1	292076-38-1/BI
E83	1	302-01-2/BI
E84	1	304650-31-5/BI
E85	1	306764-68-1/BI
E86	1	309282-30-2/BI
E87	1	311773-65-6/BI
E88	1	311799-07-2/BI
E89	1	312501-62-5/BI
E90	1	312519-16-7/BI
E91	1	312594-43-7/BI
E92	1	321679-76-9/BI
E93	1	322662-05-5/BI
E94	1	327167-87-3/BI
E95	1	329069-72-9/BI
E96	1	329350-38-1/BI
E97	1	330630-42-7/BI
E98	1	331274-84-1/BI
E99	1	331945-22-3/BI
E100	1	332161-39-4/BI
E101	1	334498-72-5/BI
E102	1	337349-59-4/BI
E103	1	337469-26-8/BI
E104	1	337498-14-3/BI
E105	1	342384-25-2/BI
E106	1	346699-98-7/BI
E107	1	353253-35-7/BI
E108	1	353273-74-2/BI
E109	1	353463-50-0/BI
E110	1	353771-45-6/BI
E111	1	353793-15-4/BI
E112	1	355000-90-7/BI
E113	1	363-58-6/BI
E114	1	364051-15-0/BI
E115	1	36817-57-9/BI
E116	1	372-31-6/BI
E117	1	383164-60-1/BI
E118	1	384729-36-6/BI
E119	1	385223-15-4/BI
E120	1	389079-78-1/BI
E121	1	390105-18-7/BI
E122	1	390174-36-4/BI
E123	1	390523-03-2/BI
E124	1	39151-19-4/BI
E125	1	392101-34-7/BI

E126	1	400064-03-1/BI
E127	1	406-00-8/BI
E128	1	40622-01-3/BI
E129	1	43071-45-0/BI
E130	1	434-75-3/BI
E131	1	4506-71-2/BI
E132	1	473390-98-6/BI
E133	1	49843-94-9/BI
E134	1	50-30-6/BI
E135	1	50-45-3/BI
E136	1	502132-61-8/BI
E137	1	5242-26-2/BI
E138	1	533-18-6/BI
E139	1	5351-85-9/BI
E140	1	5351-91-7/BI
E141	1	5467-70-9/BI
E142	1	556-90-1/BI
E143	1	569655-94-3/BI
E144	1	569655-95-4/BI
E145	1	569655-96-5/BI
E146	1	569655-97-6/BI
E147	1	569655-98-7/BI
E148	1	569655-99-8/BI
E149	1	569656-00-4/BI
E150	1	569656-01-5/BI
E151	1	569656-02-6/BI
E152	1	569656-03-7/BI
E153	1	569656-04-8/BI
E154	1	569656-05-9/BI
E155	1	569656-06-0/BI
E156	1	569656-07-1/BI
E157	1	569656-08-2/BI
E158	1	569656-09-3/BI
E159	1	569656-10-6/BI
E160	1	569656-11-7/BI
E161	1	569656-12-8/BI
E162	1	569656-13-9/BI
E163	1	569656-14-0/BI
E164	1	569656-15-1/BI
E165	1	569656-16-2/BI
E166	1	569656-17-3/BI
E167	1	569656-18-4/BI
E168	1	569656-19-5/BI
E169	1	569656-20-8/BI
E170	1	569656-21-9/BI
E171	1	569656-22-0/BI
E172	1	569656-23-1/BI
E173	1	569656-24-2/BI
E174	1	569656-25-3/BI
E175	1	569656-26-4/BI
E176	1	569656-27-5/BI
E177	1	569656-28-6/BI
E178	1	569656-29-7/BI
E179	1	60-92-4/BI
E180	1	619-05-6/BI
E181	1	619-41-0/BI
E182	1	6292-74-6/BI
E183	1	64900-65-8/BI
E184	1	6629-60-3/BI
E185	1	70-11-1/BI
E186	1	72411-52-0/BI
E187	1	7420-34-0/BI
E188	1	7440-70-2/BI

E189	1	76293-13-5/BI
E190	1	7741-53-9/BI
E191	1	7741-54-0/BI
E192	1	79-19-6/BI
E193	1	82799-44-8/BI
E194	1	82799-45-9/BI
E195	1	829-20-9/BI
E196	1	83-38-5/BI
E197	1	86358-85-2/BI
E198	1	89570-85-4/BI
E199	1	90212-73-0/BI
E200	1	91-56-5/BI
E201	1	91912-53-7/BI
E202	1	93-17-4/BI
E203	1	93-55-0/BI
E204	1	94835-69-5/BI
E205	1	96799-03-0/BI
E206	1	96799-04-1/BI
E207	1	98-59-9/BI
E208	1	98-88-4/BI
E209	1	98-95-3/BI
E210	1	108-31-6/BI
E211	1	108-38-3/BI
E212	1	119-80-2/BI
E213	1	1226-42-2/BI
E214	1	127464-60-2/BI
E215	1	306764-68-1/BI
E216	1	312501-62-5/BI
E217	1	331945-22-3/BI
E218	1	353771-45-6/BI
E219	1	40622-01-3/BI
E220	1	4506-71-2/BI
E221	1	5242-26-2/BI
E222	1	569656-05-9/BI
E223	1	569656-06-0/BI
E224	1	569656-29-7/BI
E225	1	60-92-4/BI
E226	1	619-05-6/BI
E227	1	64900-65-8/BI
E228	1	66085-59-4/BI
E229	1	7440-70-2/BI
E230	1	76293-13-5/BI
E231	1	7741-54-0/BI
E232	1	82799-44-8/BI
E233	1	91-56-5/BI

Connecting via Winsock to STN

Connecting via Winsock to STN

Connecting via Winsock to STN

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	6 MAY 11	KOREAPAT updates resume
NEWS	7 MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8 MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	9 MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	10 JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11 JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12 JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13 JUL 11	CHEMSAFE reloaded and enhanced
NEWS	14 JUL 14	FSTA enhanced with Japanese patents
NEWS	15 JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	16 AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	17 AUG 28	ADISCTI Reloaded and Enhanced
NEWS	18 AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS EXPRESS	JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 19:33:46 ON 31 AUG 2006

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.52	2.52

FILE 'REGISTRY' ENTERED AT 19:41:10 ON 31 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 AUG 2006 HIGHEST RN 905475-39-0
DICTIONARY FILE UPDATES: 30 AUG 2006 HIGHEST RN 905475-39-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10760002.str

L1 STRUCTURE UPLOADED

=> s sss l1 full

FULL SEARCH INITIATED 19:41:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS
SEARCH TIME: 00.00.01

7 ANSWERS

L2 7 SEA SSS FUL L1

=> file caplus biosis embase uspatful
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	169.46

FILE 'CAPLUS' ENTERED AT 19:41:42 ON 31 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 19:41:42 ON 31 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 19:41:42 ON 31 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 19:41:42 ON 31 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
L3 5 L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 3 DUP REM L3 (2 DUPLICATES REMOVED)

=> d ibib abs it hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:1242755 CAPLUS
DOCUMENT NUMBER: 143:472565
TITLE: Methods of treating conditions associated with an
Edg-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet
V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S.
Ser. No. 352,579.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2005261298	A1	20051124	US 2003-390428	20030314
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2002-350446P P 20020118

WO 2003-US1881	A1 20030121
US 2003-352579	B2 20030127
US 2002-350445P	P 20020118
US 2002-350447P	P 20020118
US 2002-350448P	P 20020118

OTHER SOURCE(S): MARPAT 143:472565

- AB In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.
- IT Animal cell line
(A431; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT Dopamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D2(long); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG (endothelial differentiation gene); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1 (endothelial differentiation gene 1); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-2 (endothelial differentiation gene 2); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-3 (endothelial differentiation gene 3); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-4 (endothelial differentiation gene 4); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-5 (endothelial differentiation gene 5); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-6 (endothelial differentiation gene 6); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-7 (endothelial differentiation gene 7); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-8 (endothelial differentiation gene 8); Edg-7 modulators for treating conditions associated with Edg-7 receptor)
- IT Angiogenesis
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antitumor agents
Apoptosis

Asthma
 Cardiovascular agents
 Cardiovascular system, disease
 Cell migration
 Cell proliferation
 Combination chemotherapy
 Cytotoxic agents
 Fibroblast
 Human
 Inflammation
 Ischemia
 Kidney, neoplasm
 Lung, disease
 Lung, neoplasm
 Mammary gland, neoplasm
 Myoblast
 Neuron
 Ovary, neoplasm
 Pancreas, neoplasm
 Peritoneum, neoplasm
 Platelet (blood)
 Platelet activation
 Prostate gland, neoplasm
 Stomach, neoplasm
 Thyroid gland, neoplasm
 Uterus, neoplasm
 Wound healing

(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Muscarinic receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Carbohydrates, biological studies

Nucleic acids

Organic compounds, biological studies

Proteins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line

(HT-1080; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line

(HTC; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line

(HUVEC; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Histamine receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(H1; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Calcium channel

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(L-type; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line

(MDA-MB-231; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line

(OV202, CAOV-3, MDA-MB-453; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Respiratory distress syndrome

(adult; Edg-7 modulators for treating conditions associated with Edg-7

receptor)

IT Antiarteriosclerotics
(antiatherosclerotics; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Atherosclerosis
(atherogenesis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Immune system
(autoimmune response; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Biological transport
(calcium; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Lysophosphatidic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell proliferation stimulated by; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Carcinoma
Pheochromocytoma
(cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Uterus, neoplasm
(cervix; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Intestine, neoplasm
(colon; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Intestine, neoplasm
(colorectal; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Eye
(cornea, transcorneal freezing; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Burn
(cutaneous; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Uterus, neoplasm
(endometrium; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Epithelium
(epithelial cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Sarcoma
(fibrosarcoma, cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Carcinoma
(hepatocellular, cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Liver, neoplasm
(hepatoma, cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Neoplasm
(invasiveness; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Neoplasm
(metastasis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Ovary
(ovarian cell; Edg-7 modulators for treating conditions associated with

Edg-7 receptor)

IT Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polymerization; Edg-7 modulators for treating conditions associated with
 Edg-7 receptor)

IT Intestine, neoplasm
 (small; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT Interleukin 8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synthesis; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT 5-HT receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type 5-HT1; Edg-7 modulators for treating conditions associated with
 Edg-7 receptor)

IT Angiotensin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type AT2; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT Endothelin receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (type ETA; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT Adrenoceptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α 1; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT Adrenoceptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α 2; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT Adrenoceptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (β -; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT 60-92-4, CAMP 127464-60-2, VEGF
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Edg-7 modulators for treating conditions associated with Edg-7 receptor)


IT 40622-01-3P, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid
 66085-59-4P 306764-68-1P 312501-62-5P **331945-22-3P**
 353771-45-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions
 108-38-3, 1,3-Dimethylbenzene, reactions 119-80-2 619-05-6,
 3,4-Diaminobenzoic acid 1226-42-2, 4,4'-Dimethoxybenzil 4506-71-2,
 Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[B]thiophene-3-carboxylate
 5242-26-2 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 82799-44-8
 569656-05-9 569656-06-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT 7741-54-0P 76293-13-5P, 2,4-Dimethylthioxanthen-9-one 569656-29-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (transport; Edg-7 modulators for treating conditions associated with Edg-7
 receptor)

IT 331945-22-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Edg-7 modulators for treating conditions associated with Edg-7 receptor)
 RN 331945-22-3 CAPLUS
 CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2004:703129 CAPLUS
 DOCUMENT NUMBER: 141:218996
 TITLE: Methods using Edg-7 modulators for treating conditions associated with an Edg-7 receptor
 INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 27 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167192	A1	20040826	US 2004-760002	20040116
PRIORITY APPLN. INFO.:			US 2003-440321P	P 20030116
			US 2003-454881P	P 20030313

OTHER SOURCE(S): MARPAT 141:218996
 AB The invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor-mediated biol. activity. The invention also provides a method for modulating an Edg-7 receptor-mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject. Preparation of e.g. 4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-ylidenemethyl]phenoxyacetic acid is described.

IT Animal cell line
 (A431; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
 IT Animal cell line
 (CAOV-3; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
 IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG (endothelial differentiation gene); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
 IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-1 (endothelial differentiation gene 1); Edg-7 modulators for

treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-2 (endothelial differentiation gene 2); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-3 (endothelial differentiation gene 3); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-4 (endothelial differentiation gene 4); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-5 (endothelial differentiation gene 5); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-6 (endothelial differentiation gene 6); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-7 (endothelial differentiation gene 7); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (EDG-8 (endothelial differentiation gene 8); Edg-7 modulators for
 treating conditions associated with an Edg-7 receptor)

IT Angiogenesis
 Anti-inflammatory agents
 Anti-ischemic agents
 Antiasthmatics
 Antitumor agents
 Apoptosis
 Asthma
 Cardiovascular agents
 Cardiovascular system, disease
 Cell migration
 Cell proliferation
 Combination chemotherapy
 Cytotoxic agents
 Fibroblast
 Human
 Inflammation
 Ischemia
 Kidney, neoplasm
 Lung, disease
 Lung, neoplasm
 Mammary gland, neoplasm
 Myoblast
 Neuron
 Ovary, neoplasm
 Pancreas, neoplasm
 Peritoneum, neoplasm
 Platelet (blood)
 Platelet activation
 Platelet activation
 Prostate gland, neoplasm
 Stomach, neoplasm
 Thyroid gland, neoplasm
 Uterus, neoplasm
 Wound healing

(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Carbohydrates, biological studies
 Nucleic acids
 Organic compounds, biological studies
 Proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
 (HT-1080; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
 (HTC; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
 (HUVEC; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
 (MDA-MB-231; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
 (MDA-MB-453; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
 (OV202; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Respiratory distress syndrome
 (adult; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Antiarteriosclerotics
 (antiatherosclerotics; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Atherosclerosis
 (atherogenesis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Immune system
 (autoimmune response; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Lysophosphatidic acids
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cell proliferation stimulated by; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Carcinoma
 Pheochromocytoma
 (cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Uterus, neoplasm
 (cervix; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Intestine, neoplasm
 (colon; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Intestine, neoplasm
 (colorectal; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Eye
 (cornea, transcorneal freezing; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Burn
 (cutaneous; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Uterus, neoplasm
(endometrium; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Epithelium
(epithelial cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Sarcoma
(fibrosarcoma, cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Carcinoma
(hepatocellular, cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Liver, neoplasm
(hepatoma, cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Neoplasm
(invasiveness; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Ovary
(ovarian cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Actins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polymerization; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Intestine, neoplasm
(small; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Epithelium
(surface epithelial cell injury; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Interleukin 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 26993-30-6, Sphingosine-1-phosphate
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 312501-62-5P **331945-22-3P** 353771-45-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 49581-16-0 333772-21-7 352444-98-5 352683-56-8 352694-02-1
744198-30-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions
5242-26-2 569656-05-9 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 60-92-4, Cyclic AMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation, inhibition; Edg-7 modulators for treating conditions

associated with an Edg-7 receptor)


IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mobilization; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synthesis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 331945-22-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2473740	AA	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005519915 T2 20050707 JP 2003-562260 20030121
 US 2005261298 A1 20051124 US 2003-390428 20030314
 PRIORITY APPLN. INFO.: US 2002-350445P P 20020118
 US 2002-350446P P 20020118
 US 2002-350447P P 20020118
 US 2002-350448P P 20020118
 WO 2003-US1881 W 20030121
 US 2003-352579 B2 20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g.

4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

- IT Animal cell line
(A431; Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT Animal cell line
(CAOV-3; Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT Inflammation
(Crohn's disease; Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT Intestine, disease
(Crohn's; Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1 (endothelial differentiation gene 1); Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-2 (endothelial differentiation gene 2); Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-3 (endothelial differentiation gene 3); Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-5 (endothelial differentiation gene 5); Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-6 (endothelial differentiation gene 6); Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-8 (endothelial differentiation gene 8); Edg receptor modulators for treatment of Edg receptor-associated conditions)
- IT Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antimigraine agents

Antirheumatic agents
 Antitumor agents
 Apoptosis
 Asthma
 Atherosclerosis
 Behcet's syndrome
 Cardiovascular agents
 Cardiovascular system, disease
 Cell migration
 Cell proliferation
 Cytotoxic agents
 Fibroblast
 Gastrointestinal agents
 Human
 Inflammation
 Ischemia
 Kidney, neoplasm
 Lung, disease
 Lung, neoplasm
 Mammary gland, neoplasm
 Neoplasm
 Neuron
 Ovary, neoplasm
 Pancreas, neoplasm
 Peritoneum, neoplasm
 Platelet (blood)
 Platelet activation
 Platelet activation
 Prostate gland, neoplasm
 Psoriasis
 Rheumatoid arthritis
 Stomach, neoplasm
 Thyroid gland, neoplasm
 Uterus, neoplasm
 Vasoconstriction
 Vasodilators
 Wound
 Wound healing promoters

(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Carbohydrates, biological studies

Nucleic acids

Organic compounds, biological studies

Peptides, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Edg-4; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Edg-7; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Edg; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line

(HT-1080; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(HTC; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(HUVEC; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Chemotaxis
(LPA-stimulated; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(MDA-MB-231; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(MDA-MB-453; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(OV202; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(SKOV3; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Respiratory distress syndrome
(adult; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Antiarteriosclerotics
(antiatherosclerotics; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Anemia (disease)
Autoimmune disease
(autoimmune hemolytic anemia; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Immunity
(autoimmunity; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Lysophosphatidic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell proliferation stimulated by; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Carcinoma
Myoblast
Pheochromocytoma
(cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Artery
(cerebral, vasoconstriction; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Uterus, neoplasm
(cervix; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Resolution (separation)
(chromatog.; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Infection
(chronic active hepatitis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Inflammation
Kidney, disease
(chronic glomerulonephritis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Temperature effects, biological
(cold, transcorneal freezing; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Intestine, neoplasm

(colon; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Intestine, neoplasm
(colorectal; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Burn
(cutaneous; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Meninges
(disease, subarachnoid hemorrhage; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Uterus, neoplasm
(endometrium; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Blood vessel
(endothelium; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Epithelium
(epithelial cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Carcinoma
(epithelioid; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Sarcoma
(fibrosarcoma, cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Carcinoma
(hepatocellular; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Liver, neoplasm
(hepatoma; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(level of; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lysophosphatidic acid; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Neoplasm
(metastasis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Headache
(migraine; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Kidney, disease
(non-glomerular nephrosis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Blood vessel, disease
(occlusion; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Egg
(oocyte, *Xenopus laevis*; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT *Xenopus laevis*
(oocyte; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Ovary

(ovarian cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Actins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polymerization; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Intestine, neoplasm
 (small; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Blood vessel, disease
 (spasm; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Brain, disease
 (stroke; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Hemorrhage
 (subarachnoid; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Injury
 (surface epithelial cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Interleukin 8
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synthesis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Lupus erythematosus
 (systemic; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Purpura (disease)
 (thrombocytopenic, chronic; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Inflammation
 Intestine, disease
 (ulcerative colitis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Endothelium
 (vascular; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Hepatitis
 (viral, chronic active; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 182762-25-0, GenBank X83864 218763-60-1, GenBank AJ000479 259476-69-2, GenBank AF233092 262400-57-7, GenBank AF233090 384729-36-6, GenBank U78192 385223-15-4, GenBank AF011466 390105-18-7, GenBank AF034780 390174-36-4, GenBank AF233365 390523-03-2, GenBank AF317676 392101-34-7, GenBank AF127138
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 473390-98-6
 RL: FMU (Formation, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 353273-74-2P 569655-94-3P 569655-95-4P 569655-96-5P 569656-23-1P 569656-24-2P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

conditions)

IT 94835-69-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 7741-53-9P 40622-01-3P 173275-26-8P 304650-31-5P 311799-07-2P
 312501-62-5P 312519-16-7P **331945-22-3P** 334498-72-5P
 342384-25-2P 353253-35-7P 353771-45-6P 355000-90-7P 569656-08-2P
 569656-09-3P 569656-10-6P 569656-11-7P 569656-12-8P 569656-13-9P
 569656-14-0P 569656-15-1P 569656-16-2P 569656-17-3P 569656-18-4P
 569656-19-5P 569656-20-8P 569656-21-9P 569656-25-3P 569656-26-4P
 569656-27-5P 569656-29-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 49843-94-9 90212-73-0 107235-67-6 136382-28-0 171286-07-0
 177360-28-0 292076-38-1 306764-68-1 309282-30-2 311773-65-6
 312594-43-7 321679-76-9 322662-05-5 327167-87-3 329350-38-1
 330630-42-7 331274-84-1 332161-39-4 337349-59-4 337469-26-8
 337498-14-3 346699-98-7 353463-50-0 353793-15-4 364051-15-0
 383164-60-1 389079-78-1 400064-03-1 569655-97-6 569655-98-7
 569656-22-0 569656-28-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 50-30-6, 2,6-Dichlorobenzoic acid 50-45-3, 2,3-Dichlorobenzoic acid
 70-11-1, 2-Bromoacetophenone 79-19-6, Thiosemicarbazide 83-38-5,
 2,6-Dichlorobenzaldehyde 91-56-5, 1H-Indole-2,3-dione 93-17-4,
 3,4-Dimethoxyphenylacetone nitrile 93-55-0, Propiophenone 98-59-9,
 p-Toluenesulfonyl chloride 98-88-4, Benzoyl chloride 98-95-3,
 Nitrobenzene, reactions 100-65-2, N-Phenylhydroxylamine 108-31-6,
 Maleic anhydride, reactions 108-38-3, 1,3-Dimethylbenzene, reactions
 120-72-9, Indole, reactions 123-11-5, p-Anisaldehyde, reactions
 140-75-0, 4-Fluorobenzylamine 302-01-2, Hydrazine, reactions 363-58-6
 372-31-6, Ethyl 4,4,4-trifluoroacetoacetate 406-00-8,
 4-Fluorophenylhydroxylamine 434-75-3, 2-Chloro-6-fluorobenzoic acid
 533-18-6, o-Tolyl acetate 556-90-1, Pseudothiohydantoin 619-05-6,
 3,4-Diaminobenzoic acid 619-41-0, 2-Bromo-4'-methylacetophenone
 829-20-9 1226-42-2, 4,4'-Dimethoxybenzil 1468-83-3, 3-Acetylthiophene
 1476-23-9, Allyl isocyanate 1572-10-7 2642-63-9, 3',4'-
 Dichloroacetophenone 4506-71-2 5242-26-2 5351-85-9 6629-60-3,
 Ethylhydrazine oxalate 13100-05-5 13380-67-1 19541-95-8 23448-86-4
 23821-37-6 36817-57-9 39151-19-4 64900-65-8, 2-Chlorobenzenesulfonyl
 isocyanate 72411-52-0 82799-44-8 89570-85-4 96799-03-0
 96799-04-1 569656-04-8 569656-05-9 569656-06-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 5351-91-7P 5467-70-9P 6292-74-6P 7420-34-0P 7741-54-0P
 43071-45-0P 76293-13-5P 82799-45-9P 86358-85-2P 91912-53-7P
 112612-58-5P 113054-02-7P 149246-80-0P 149246-86-6P 208519-10-2P
 208519-15-7P 329069-72-9P 502132-61-8P 569655-99-8P 569656-00-4P
 569656-01-5P 569656-02-6P 569656-03-7P 569656-07-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 26993-30-6, Sphingosine-1-phosphate

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (calcium mobilization stimulated by; Edg receptor modulators for
 treatment of Edg receptor-associated conditions)

IT 60-92-4, Cyclic AMP
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (formation inhibition; Edg receptor modulators for treatment of Edg
 receptor-associated conditions)

IT 7440-70-2, Calcium, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mobilization; Edg receptor modulators for treatment of Edg
 receptor-associated conditions)

IT 127464-60-2, Vascular endothelial growth factor
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (synthesis; Edg receptor modulators for treatment of Edg
 receptor-associated conditions)

IT **331945-22-3P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (Edg receptor modulators for treatment of Edg receptor-associated
 conditions)

RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-
 dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)

